Report Sections

See All Reports

  • HP:0001626: Abnormality of the cardiovascular system
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0001626: Abnormality of the cardiovascular system

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (64)


    Name (Synonyms) Correlation
    drug1047 Convalescent Plasma Wiki 0.45
    drug1060 Convalescent plasma Wiki 0.26
    drug1045 Convalescent COVID 19 Plasma Wiki 0.24
    Name (Synonyms) Correlation
    drug1052 Convalescent Plasma Transfusion Wiki 0.24
    drug1049 Convalescent Plasma (anti-SARS-CoV-2 plasma) Wiki 0.24
    drug1048 Convalescent Plasma (CP) Wiki 0.24
    drug3950 Temporarily holding the RAAS inhibitor [intervention] Wiki 0.17
    drug1819 Hydroxychloroquine, Azithromycin Wiki 0.17
    drug1820 Hydroxychloroquine, Clindamycin Wiki 0.17
    drug2602 Non-convalescent Plasma (control plasma) Wiki 0.17
    drug3704 Standard Donor Plasma Wiki 0.17
    drug40 1: discontinuation of RAS blocker therapy Wiki 0.17
    drug3700 Standard COVID-19 therapies Wiki 0.17
    drug738 COVID-19 Antibody testing Wiki 0.17
    drug2289 Masked Saline Placebo Wiki 0.17
    drug2587 No interverntion Wiki 0.17
    drug1031 Control (albumin 5%) Wiki 0.17
    drug842 Cannabidiol, pharmaceutically produced with < 5 ppm THC Wiki 0.17
    drug2822 Passed infection of SARS-CoV-2 Wiki 0.17
    drug292 Angiotensin II Receptor Blockers Wiki 0.17
    drug365 Assessment of cardiovascular diseases and cardiovascular risk factors Wiki 0.17
    drug1228 Digital cardiac Counseling Wiki 0.17
    drug2610 Non-invasive cardiac imaging Wiki 0.17
    drug2890 Phone-call screening and management by a medical student/general practitioner tandem Wiki 0.17
    drug1821 Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki 0.17
    drug1964 Interferon-Alpha2B Wiki 0.17
    drug3846 Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) Wiki 0.17
    drug1357 Electrocardiogram, telemetry, echocardiogram, laboratory values Wiki 0.17
    drug4617 non-interventional Wiki 0.17
    drug1486 FFP Wiki 0.17
    drug770 COVID-19 exposure Wiki 0.17
    drug1057 Convalescent Serum Wiki 0.17
    drug1278 Drugs and supportive care Wiki 0.17
    drug1822 Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki 0.17
    drug1823 Hydroxychloroquine, Doxycycline Wiki 0.17
    drug3702 Standard Care Therapy Wiki 0.17
    drug26 12 weeks of bicycle exercise Wiki 0.17
    drug3263 Random Donor Plasma Wiki 0.17
    drug3918 Tele-medicine platform Wiki 0.17
    drug1044 ConvP Wiki 0.17
    drug4611 non Wiki 0.17
    drug52 2: continuation of RAS blocker therapy Wiki 0.17
    drug1053 Convalescent Plasma as Therapy for Covid-19 patients Wiki 0.17
    drug3213 RAAS inhibitor [continued standard of care] Wiki 0.17
    drug735 COVID visitation restrictions Wiki 0.17
    drug294 Angiotensin converting enzyme inhibitor Wiki 0.12
    drug1527 Fiberoptic Endoscopic Evaluation of Swallowing Wiki 0.12
    drug1880 Icosapent ethyl Wiki 0.12
    drug933 Clinical data Wiki 0.10
    drug3813 Supportive Care Wiki 0.10
    drug4628 observational Wiki 0.10
    drug1959 Interferon Beta-1A Wiki 0.09
    drug1127 DAS181 Wiki 0.07
    drug2176 Losartan Wiki 0.06
    drug3502 Saline Wiki 0.05
    drug1396 Enoxaparin Wiki 0.05
    drug2365 Methylprednisolone Wiki 0.05
    drug2029 Ivermectin Wiki 0.04
    drug3738 Standard of care Wiki 0.03
    drug3319 Remdesivir Wiki 0.03
    drug4025 Tocilizumab Wiki 0.03
    drug3728 Standard of Care Wiki 0.03
    drug2916 Placebo Wiki 0.02
    drug1775 Hydroxychloroquine Wiki 0.02

    Correlated MeSH Terms (39)


    Name (Synonyms) Correlation
    D002318 Cardiovascular Diseases NIH 0.99
    D018376 Cardiovascular Abnormalities NIH 0.17
    D015428 Myocardial Reperfusion Injury NIH 0.17
    Name (Synonyms) Correlation
    D015427 Reperfusion Injury NIH 0.17
    D006333 Heart Failure NIH 0.15
    D003327 Coronary Disease NIH 0.13
    D019965 Neurocognitive Disorders NIH 0.12
    D013896 Thoracic Diseases NIH 0.12
    D000787 Angina Pectoris NIH 0.12
    D050197 Atherosclerosis NIH 0.12
    D000073296 Noncommunicable Diseases NIH 0.12
    D054143 Heart Failure, Systolic NIH 0.12
    D009202 Cardiomyopathies NIH 0.10
    D006330 Heart Defects, Congenital NIH 0.10
    D006331 Heart Diseases NIH 0.09
    D014029 Tobacco Use Disorder NIH 0.09
    D003693 Delirium NIH 0.08
    D003680 Deglutition Disorders NIH 0.07
    D006973 Hypertension NIH 0.07
    D054058 Acute Coronary Syndrome NIH 0.07
    D001523 Mental Disorders NIH 0.07
    D000066553 Problem Behavior NIH 0.06
    D050177 Overweight NIH 0.06
    D009205 Myocarditis NIH 0.06
    D003324 Coronary Artery Disease NIH 0.06
    D008173 Lung Diseases, Obstructive NIH 0.05
    D002908 Chronic Disease NIH 0.05
    D009203 Myocardial Ischemia NIH 0.04
    D008171 Lung Diseases, NIH 0.04
    D014947 Wounds and Injuries NIH 0.03
    D012141 Respiratory Tract Infections NIH 0.03
    D003141 Communicable Diseases NIH 0.02
    D007239 Infection NIH 0.02
    D016638 Critical Illness NIH 0.02
    D011024 Pneumonia, Viral NIH 0.02
    D018352 Coronavirus Infections NIH 0.02
    D013577 Syndrome NIH 0.02
    D011014 Pneumonia NIH 0.01
    D045169 Severe Acute Respiratory Syndrome NIH 0.01

    Correlated HPO Terms (15)


    Name (Synonyms) Correlation
    HP:0001635 Congestive heart failure HPO 0.15
    HP:0001681 Angina pectoris HPO 0.12
    HP:0002621 Atherosclerosis HPO 0.12
    Name (Synonyms) Correlation
    HP:0001638 Cardiomyopathy HPO 0.10
    HP:0001627 Abnormal heart morphology HPO 0.10
    HP:0000822 Hypertension HPO 0.07
    HP:0002015 Dysphagia HPO 0.07
    HP:0000708 Behavioral abnormality HPO 0.06
    HP:0001677 Coronary artery atherosclerosis HPO 0.06
    HP:0012819 Myocarditis HPO 0.06
    HP:0006536 Pulmonary obstruction HPO 0.05
    HP:0001658 Myocardial infarction HPO 0.04
    HP:0002088 Abnormal lung morphology HPO 0.04
    HP:0011947 Respiratory tract infection HPO 0.03
    HP:0002090 Pneumonia HPO 0.01

    Clinical Trials

    Navigate: Correlations   HPO

    There are 34 clinical trials


    1 Impact of a Novel Coronavirus (2019-nCoV) Outbreak on Public Anxiety and Cardiovascular Disease Risk in China

    Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last year.

    NCT04255940
    Conditions
    1. Cardiovascular Death; Major Adverse Cardiovascular Events
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Measure: Cardiovascular Death

    Time: 3 months

    Secondary Outcomes

    Measure: Major Adverse Cardiovascular Events

    Time: 3 months

    Measure: Times From symptom onset to hospital arrival

    Time: 3 months

    Measure: Anxiety

    Time: 3 months
    2 Retrospective Study of Myocardial Damage in COVID-19

    This study aims to investigate the clinical characteristics, the incidence of myocardial injury, and the influence of myocardial injury on the prognosis in COVID-19 patients. There is no additional examination and treatment for this project.

    NCT04312464
    Conditions
    1. COVID-19
    2. Cardiovascular Diseases
    Interventions
    1. Other: non
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: The myocardial injury incidence of COVID-19 patients

    Measure: The myocardial injury incidence

    Time: 75 days

    Description: The risk factors analysis for the death of COVID-19 patients

    Measure: The risk factors analysis for the death

    Time: 75 days

    Secondary Outcomes

    Description: The clinical characteristics description of COVID-19 patients

    Measure: Clinical characteristics

    Time: 75 days

    Description: The clinical course description of COVID-19 patients

    Measure: Clinical course

    Time: 75 days

    Description: The clinical characteristics and prognosis analysis in different cardiovascular comorbidity of COVID-19 patients

    Measure: Cardiovascular comorbidity

    Time: 75 days

    Description: Analysis of causes of death in COVID-19 patients

    Measure: Analysis of causes of death

    Time: 75 days
    3 Time of Recovery and Prognostic Factors of COVID-19 Pneumonia

    It has been reported that nearly half of the patients who are hospitalized for Covid-19 pneumonia have on admission old age or comorbidities. In particular, hypertension was present in 30% of the cases, diabetes in 19%, coronary heart disease in 8% and chronic obstructive lung disease in 3% of the patients. Amazingly, in the two major studies published in the Lancet (Zhou F et al Lancet 2020) and in the New England Journal of Medicine (Guan W et al 2020), the weight of the subjects as well their body mass index (BMI) were omitted. However, obesity, alone or in association with diabetes, can be a major predisposition factor for Covid-19 infection. The primary end-point of our prospective, observational study is to assess the recovery rate in patients with diagnosis of Covid-19 pneumonia. Among the other secondary end-points, we intend to find the predictors of the time to clinical improvement or hospital discharge in patients affected by Covid-19 pneumonia.

    NCT04324684
    Conditions
    1. Pneumonia, Viral
    2. Hypertension
    3. Diabetes Mellitus
    4. Obesity
    5. Cardiovascular Diseases
    6. Obstructive Lung Disease
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases Lung Diseases, Obstructive Cardiovascular Diseases
    HPO:Abnormal lung morphology Abnormality of the cardiovascular system Pneumonia Pulmonary obstruction

    Primary Outcomes

    Description: mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.

    Measure: rate of recovery

    Time: 3 weeks

    Secondary Outcomes

    Description: comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complications

    Measure: time to improvement

    Time: 3 weeks

    Description: the efficacy of different pharmaceutical treatment against Covid-19

    Measure: efficacy of treatments

    Time: 3 weeks

    Description: liver, kidney or multiorgan failure, cardiac failure

    Measure: organ failure

    Time: 3 weeks
    4 Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY

    CAPACITY (www.capacity-covid.eu) is a registry of patients with COVID-19 across Europe and has been established to answer questions on the role of cardiovascular disease in this pandemic. It is an extension of the Case Record Form (CRF) that was released by the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) and WHO (World Health Organisation) in response to the emerging outbreak of COVID-19.

    NCT04325412
    Conditions
    1. COVID-19; Cardiovascular Diseases
    MeSH:Coronavirus Infections Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Measure: The incidence of cardiovascular complications in patients with COVID-19

    Time: 30 days
    5 Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic

    Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.

    NCT04325867
    Conditions
    1. Angina Pectoris
    2. Acute Coronary Syndrome
    3. Coronary Syndrome
    4. Coronary Artery Disease
    5. Angioplasty
    6. Stent Restenosis
    7. Hypertension
    8. Heart Failure, Systolic
    9. Depression, Anxiety
    10. Covid-19
    11. Isolation, Social
    Interventions
    1. Other: Tele-medicine platform
    MeSH:Heart Failure Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Angina Pectoris Heart Failure, Systolic Syndrome
    HPO:Abnormal left ventricular function Abnormality of the cardiovascular system Angina pectoris Congestive heart failure Coronary artery atherosclerosis Myocardial infarction Right ventricular failure

    Primary Outcomes

    Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context

    Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients

    Time: 6 months

    Description: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);

    Measure: Number of patients included in this platform

    Time: 6 months

    Secondary Outcomes

    Description: Will be the number of sessions per patient multiplied with the number of patients included

    Measure: Number of consultations/sessions given

    Time: 6 months
    6 Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

    The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

    NCT04327479
    Conditions
    1. Cardiovascular Diseases
    2. Cardiovascular Risk Factor
    3. SARS
    Interventions
    1. Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: mortality of any cause

    Measure: All-cause mortality

    Time: During 1 year follow-up

    Secondary Outcomes

    Description: mortality of any cause

    Measure: 30-day mortality

    Time: Within 30 days after inclusion

    Description: Myocardial infarction, stroke, or CV death

    Measure: Major adverse cardiovascular events

    Time: During 1 year follow-up
    7 ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study

    Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused an international outbreak of respiratory illness described as COVID-19. Individuals with a history of cardiovascular disease develop a more severe illness and have higher rates of death. Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of infection, there are ongoing scientific discussions on whether they should be stopped or continued in patients with COVID-19. It is crucial to determine whether RAS blockers should be discontinued or not in patients with COVID-19.

    NCT04329195
    Conditions
    1. History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection
    Interventions
    1. Drug: 1: discontinuation of RAS blocker therapy
    2. Drug: 2: continuation of RAS blocker therapy
    MeSH:Infection Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Measure: Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)

    Time: from day 0 to day 28 or hospital discharge

    Secondary Outcomes

    Measure: Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28

    Time: at day 28

    Measure: Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.

    Time: at days 7, 14 and 28

    Measure: Number of days alive free of oxygen.

    Time: from day 0 to day 28 or hospital discharge

    Measure: Number of days alive outside hospital until day28

    Time: at day28

    Measure: Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28

    Time: at day28

    Measure: Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28

    Time: at day28

    Measure: Number of days alive free of ICU admission until day28

    Time: at day28

    Measure: Rate of all-cause mortality at day 28

    Time: at day 28

    Measure: Rate of cardiovascular death at day 28

    Time: at day 28

    Measure: Number of days alive free of acute kidney injury until hospital discharge

    Time: at day 28 to hospital discharge
    8 Phase IV Observational Study to Associate Hypertension and Hypertensinon Treatment to COVID19

    Multicentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.

    NCT04331574
    Conditions
    1. COVID-19
    2. Hypertension
    3. Cardiovascular Diseases
    MeSH:Hypertension Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system Hypertension

    Primary Outcomes

    Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.

    Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

    Time: 3 months

    Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19

    Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents

    Time: 3 months

    Secondary Outcomes

    Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severity

    Measure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity

    Time: 3 months
    9 Cardiovascular Manifestations of Hospitalized Patients With Coronavirus Disease 2019

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first reports of COVID-19 came from Wuhan, China in December of 2019. Since then, the disease has spread rapidly around the globe, accounting for thousands of deaths in multiple countries. On March 11th, 2020, the World Health Organization declared COVID-19 as a pandemic. Although COVID-19 manifests primarily as a respiratory illness, several cardiovascular implications have been reported related to its natural course and treatment. Its exact effect on the cardiovascular system though is currently unknown. Therefore, we propose a retrospective, observational, case-control study looking for cardiovascular manifestations of COVID-19, including laboratory evidence of myocardial injury, electrocardiographic changes, arrhythmias and echocardiographic abnormalities. Hospitalized patients admitted with fever, cough, sore throat, and/or dyspnea who were tested positive for SARS-CoV-2 will be included in our study and will be matched based on their age and gender with patients admitted with similar symptoms who tested negative for SARS-CoV-2. The electronic medical charts of the study subjects will be reviewed and relevant demographic, clinical, laboratory and imaging findings will be deidentified and recorded. Since our study will be a retrospective chart review study it carries minimal risk for the patients and the investigators. Cardiovascular disease associated with COVID-19 might be contributing to the high mortality rates and its recognition will allow for prevention, early diagnosis and appropriate treatment. This will be the first, large, case-control study assessing cardiovascular involvement of COVID-19 in a well-defined cohort of patients.

    NCT04335630
    Conditions
    1. Cardiovascular Diseases
    2. COVID
    Interventions
    1. Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Measure: Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.

    Time: One year

    Secondary Outcomes

    Measure: Prevalence of pericarditis, pericardial effusion, valvular disease.

    Time: One year

    Measure: Identification of characteristic electrocardiographic patterns related to COVID-19

    Time: One year

    Measure: Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.

    Time: One year

    Measure: Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19

    Time: One year

    Measure: Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19

    Time: One year

    Measure: Role of insurance type on clinical outcomes of patients with COVID-19

    Time: One year

    Measure: Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications

    Time: One year

    Measure: Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications

    Time: One year
    10 The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury

    COVID-19 is associated with complications including ARDS and myocardial injury, which informs prognosis and patient outcome. The laboratory plans to perform immunophenotyping of peripheral T-cells in patients with COVID-19 and complications (ARDS, ITU admission, myocardial injury) and map this against clinical patient outcomes. The aim is to determine if there is a specific T-cell immunophenotype associated with COVID-19 and/or complications, which can be used to inform prognosis and potential therapies.

    NCT04340921
    Conditions
    1. Cardiovascular Disease Acute
    2. Cardiomyopathies
    3. COVID
    Interventions
    1. Biological: COVID-19 exposure
    MeSH:Cardiovascular Diseases Cardiomyopathies
    HPO:Abnormality of the cardiovascular system Cardiomyopathy

    Primary Outcomes

    Description: T-cell immunophenotype

    Measure: T-cell immunophenotype

    Time: 12 months from enrollment

    Secondary Outcomes

    Description: death, survival to discharge

    Measure: Mortality

    Time: 12 months from enrolment

    Description: Admission to the intensive care

    Measure: ITU admission

    Time: 12 months from enrolment

    Description: Defined by troponin rise to >99th centile

    Measure: Myocardial injury

    Time: 12 months from enrolment
    11 Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial

    Following the announcement of the containment of the population due to the COVID-19 epidemic on March 17, 2020 in France, a notable decrease in the number of consultations in general practice was reported. Patients no longer contact their general practitioner, including those with regular follow-up for one or more chronic conditions. This observation raised worries since it could lead to delay or failure in detecting decompensations / complications of these chronic conditions by a lack of recourse to care. Thus, an urgent message from the National Health Department (Direction Générale de la Santé - DGS) was adressed on April 8, 2020 to the health professionals regarding the organization of care aside from COVID-19. The main recommendation was "that the personal physician or the corresponding specialist should contact the most fragile patients with chronic condition to ensure follow-up and detect any risk of decompensation ". Such fragile patients are in great numbers, up to more than 200 for an average general practitioner. Therefore, although this recommendation is regarded as "essential in view of the health needs of the population", it will prove quite difficult to follow without the help of a skilled external assistance that can be quickly mobilized. The COVIQUEST project is a cluster randomized trial in general practice designed to assess the optimizationg of the screening and management of patients with chronic condition at risk of decompensation through a collaboration between the general practitioner and a medical student. The trial will focus on patients wit cardiovascular conditions aged 70 or more and patients with mental health conditions. These conditions are both highly prevalent in general practice and both at risk of severe short-term complications. Practices will be randomly assigned to a group (A or B). In group A, students will start by contacting patients with cardiovascular conditions; in group B they will start by contacting patients patients with mentral health conditions. The students will call these patients on the phone and ask them specific questions about their health, their needs, and if they want their general practitioner to call them back. The student will then transmit this information to the general practitioner who will decide on the best care to offer the patient. The primary outcome is defined as the occurrence of hospitalization during a one-month period after the phone call. It will be collected by a second phone call from the medical student. This time, all patients will be contacted, i.e. both patients with mental illness and cardiovascular patients, whatever the group. Thus, patients allocated to the control groups (i.e. patients with mental illness from group A and cardiovascular patients from group B) will also benefit from the intervention at 1 month: again, students will ask patients about their health and whether they want their general practitioner to call them back. This approach has several advantages: 1. all patients will benefit from a phone call, in accordance with the recommendations of the DGS, 2. the involvement of students, competent in medical interviews and quickly mobilizable, will help general practitioners, on the front line of many missions, without any health risk linked to the contagiousness of COVID-19 for students, 3. randomizing the call order will allow to assess with a high level of evidence the impact of such an organization on hospitalizations, for two families of diseases with high prevalence. The trial will involve at least nine French regions. Considering that the general practitioner's patient base numbers an average of 110 patients with chronic cardiovascular disease or chronic mental illness, and that at least 25 general practitioners per region participate in the study, we can expect that 22,000 patients will benefit from the intervention of this study.

    NCT04359875
    Conditions
    1. Cardiovascular Diseases
    2. Mental Disorder
    Interventions
    1. Behavioral: Phone-call screening and management by a medical student/general practitioner tandem
    MeSH:Cardiovascular Diseases Mental Disorders
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Hospitalization over a one month period. The primary outcome will be collected by a phone call from a medical student to the patient 1 month after randomization date. Hospitalizations (date, location, length, if available, and reason) will be collected. Because there will be many patients to be called for each practitioner, we expect these phone call to occur within a few days after day 28.

    Measure: Hospitalization(s) at 1 month

    Time: 1 month

    Secondary Outcomes

    Description: In the experimental group only: proportion of patients for whom the practitioner had to call back after the medical student had phoned (just after allocation of the practice to the experimental group) at 1 month.

    Measure: Phone-call from the general practitioner (in the experimental group only)

    Time: 1 month

    Description: Mortality will be reported after checking with the city of the patient's home if there is no response to the phone call

    Measure: Mortality at 1 month

    Time: 1 month

    Description: Number of general practitioner consultations and teleconsultations (and time of general practitioner consultation, i.e. during the containment period or not) using data from the French Health National (SNDS) Database

    Measure: Use of primary care

    Time: 6 months

    Description: Number of consultations with another medical specialist (and time of consultation, i.e. during the containment period or not) using data from the French Health National (SNDS) Database

    Measure: Use of secondary care

    Time: 6 months

    Description: Number of prescriptions related to the chronic disease that were dispensed by the pharmacy using data from the French Health National (SNDS) Database

    Measure: Number of prescriptions related to the chronic disease dispensed by the pharmacy

    Time: 6 months

    Description: Number of hospitalizations using data from the French Health National (SNDS) Database

    Measure: Number of hospitalization(s)

    Time: 6 months

    Description: Time to hospitalization using data from the French Health National (SNDS) Database

    Measure: Time to hospitalization(s)

    Time: 6 months

    Description: Hospitalization duration using data from the French Health National (SNDS) Database

    Measure: Hospitalization(s)' durations

    Time: 6 months

    Description: Reason for hospitalization using data from the French Health National (SNDS) Database

    Measure: Reasons for hospitalization(s)

    Time: 6 months

    Description: Number of deaths using data from the French Health National (SNDS) Database

    Measure: Mortality at 6 months

    Time: 6 months

    Description: Only for patients in the COVIQuest_CV sub-trial: Cardiovascular events (MACE): nonfatal stroke, nonfatal myocardial infarction, cardiovascular death and hospitalization for heart failure using data from the French Health National (SNDS) Database

    Measure: Cardiovascular events (MACE)

    Time: 6 months

    Description: Only for patients in the COVIQuest_MH sub-trial: Psychotropic drugs consumption using data from the French Health National (SNDS) Database

    Measure: Psychotropic drugs

    Time: 6 months
    12 Long-term Effects of Coronavirus 2019 Disease on the Cardiovascular System in Patients Who Have Undergone a Diagnostic Nasopharyngeal Swab for SARS-CoV-2. CV COVID-19 Registry

    Patients presenting with the coronavirus-2019 disease (COVID-19) have a very high risk of cardiovascular adverse events, including death from cardiovascular causes. Unfortunately, there are no reliable statistics on the frequency and severity of these complications during the index hospitalization. Moreover, the long-term cardiovascular outcomes of these patients are entirely unknown. The investigators aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and determine their long-term cardiovascular outcomes.

    NCT04359927
    Conditions
    1. Sars-CoV2
    2. Covid19
    3. Cardiovascular Diseases
    4. Cardiovascular Risk Factor
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Cardiovascular mortality is defined according to the Academic Research Consortium-2 and will be independently adjudicated by a Clinical Events Committee.

    Measure: Cardiovascular mortality

    Time: 1-year

    Secondary Outcomes

    Description: Acute myocardial infarction is defined according to the Academic Research Consortium-2.

    Measure: Acute myocardial infarction

    Time: 1-year

    Description: Stroke is defined according to the Academic Research Consortium-2.

    Measure: Stroke

    Time: 1-year

    Other Outcomes

    Description: Documented hospital admission due to heart failure

    Measure: Heart failure hospitalization

    Time: 1-year

    Description: Documented by a chest computed tomography

    Measure: Pulmonary embolism

    Time: 1-year

    Description: Documented hospital admission due to any cardiac arrhythmia

    Measure: Cardiac arrhythmias

    Time: 1-year
    13 How Are You Coping? Assessing the Psychological, Social, and Economic Impacts of an Emerging Pandemic

    A dynamic analytical tool is being implemented to monitor the health, psychosocial and economic impacts of the COVID-19 pandemic as the crisis unfolds. A longitudinal survey is distributed via a network of hospitals, provincial/national organizations and web platforms. The survey information can be linked to provincial health administrative data and metrics derived from social media activity based on artificial intelligence methods. Targeted questions are included for critical populations such as healthcare workers and people with chronic illnesses.

    NCT04369690
    Conditions
    1. COVID-19
    2. Chronic Disease
    3. Psychiatric Disorder
    4. Cardiovascular Diseases
    MeSH:Cardiovascular Diseases Chronic Disease Mental Disorders Problem Behavior
    HPO:Abnormality of the cardiovascular system Behavioral abnormality

    Primary Outcomes

    Description: Cohen's Perceived Stress Scale (scores ranged from 0 to 40, higher scores indicating worse stress)

    Measure: Mental health - Stress

    Time: through study completion, estimated to 8 months

    Description: Generalized Anxiety Disorder Scale (scores ranged from 0 to 21, higher scores indicating worse anxiety)

    Measure: Mental health - Anxiety

    Time: through study completion, estimated to 8 months

    Description: Quick Inventory of Depressive Symptomatology-Self-report, short version (scores ranged from 0 to 27, higher scores indicating worse depression)

    Measure: Mental health - Depression

    Time: through study completion, estimated to 8 months

    Secondary Outcomes

    Description: Measure of Moral Distress - Healthcare Professionals (scores ranged from 0 to 432, higher scores indicating worse moral distress)

    Measure: Moral distress in healthcare workers

    Time: through study completion, estimated to 8 months

    Description: Rushton Moral Resilience Scale (scores ranged from 1 to 4, higher scores indicating more resiliency)

    Measure: Moral resilience in healthcare workers

    Time: through study completion, estimated to 8 months

    Description: Frequency of interacting with other people (daily, weekly, monthly, less often than monthly)

    Measure: Social life

    Time: through study completion, estimated to 8 months

    Description: Fever, Cough, Difficulty breathing or shortness of breath, Tiredness, Aches and pains, Nasal congestion, Runny nose, Sore throat, Diarrhea (Mild Moderate, Severe, N/A)

    Measure: COVID-9 symptoms

    Time: through study completion, estimated to 8 months

    Description: Mortality (Yes/No): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

    Measure: Adverse health long-term outcome

    Time: 5 years before the outbreak and two years after

    Description: Hospitalizations (total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

    Measure: Health care utilization - Inpatient

    Time: 5 years before the outbreak and two years after

    Description: Emergency Department visits (Total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

    Measure: Health care utilization - ER

    Time: 5 years before the outbreak and two years after

    Description: Outpatient visits: https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx

    Measure: Health care utilization - Outpatient

    Time: 5 years before the outbreak and two years after

    Description: Pittsburgh Sleep Quality Index (scores ranged from 0 to 21, higher scores indicating worse sleep disturbances)

    Measure: Sleep

    Time: through study completion, estimated to 8 months
    14 Prospective Monitoring of Drug Safety and the Occurrence of Complications During Hospitalization in Patients With Cardiovascular Diseases With COVID-19

    Hospitalized patients with COVID-19 will be included in the study in centers around Poland. After the hospitalization, a short questionnaire will be completed, including pre-hospitalization diagnoses, pre-hospitalization medications, clinical status on admission, the course, complication and the duration of hospitalization. The questionnaire will be available in paper form and on-line.

    NCT04374110
    Conditions
    1. COVID
    2. Hypertension
    3. Cardiovascular Diseases
    4. Cardiovascular Risk Factor
    Interventions
    1. Other: Clinical data
    MeSH:Hypertension Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system Hypertension

    Primary Outcomes

    Description: Death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

    Measure: Adverse events

    Time: through study completion, an average of 2 weeks

    Secondary Outcomes

    Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

    Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

    Time: through study completion, an average of 2 weeks

    Description: Ventilation during hospitalization

    Measure: Ventilation during hospitalization

    Time: through study completion, an average of 2 weeks

    Description: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke analyzed separately for each of the endpoints

    Measure: Number of participants with death, myocardial infarction, heart failure, myocarditis, acute renal failure, stroke

    Time: prolonged follow up, through study completion, an average of one year
    15 A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer

    The coronavirus disease 2019 (COVID-19) global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused considerable morbidity and mortality in over 170 countries. Increasing age and burden of cardiovascular comorbidities are associated with a worse prognosis among patients with COVID-19. In addition, serologic markers of more severe disease including coagulation abnormalities and thrombocytopenia, are not uncommon among patients hospitalized with severe COVID-19 infection and are more common in patients who died in-hospital. As the COVID-19 pandemic continues to grow, there is a pressing need to identify safe, effective, and widely available therapies that can be scaled and rapidly incorporated into clinical practice. Understanding the putative mechanism of increased mortality risk associated with abnormal coagulation function and cardiac injury is critical to guide studies of promising therapeutic interventions. Published and anecdotal reports indicate that endothelial dysfunction and thrombosis are common in critically ill patients with COVID-19, including reports of diffuse microvascular thrombosis in the lungs, heart, liver, and kidneys. Patients with cardiovascular disease (CVD) and CVD risk factors are known to have endothelial dysfunction and a heightened risk of thrombosis. A recent study of COVID-19 inpatients from Wuhan, China observed that an elevated D-dimer level greater than 1 ug/mL was associated with an 18 times higher risk of in-hospital death, underscoring the importance of increased coagulation activity as a potential modifiable risk marker that may drive end-organ injury. Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease, and the association between coagulopathy and adverse outcomes in patients with sepsis, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy and safety.

    NCT04377997
    Conditions
    1. Cardiovascular Diseases
    2. COVID-19
    Interventions
    1. Drug: Enoxaparin
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Aim 1 - Risk of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

    Measure: Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

    Time: 12 weeks

    Description: Aim 2 - Risk of major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

    Measure: Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

    Time: 12 weeks
    16 COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry

    Background: Coronavirus disease (COVID-19) is a tremendous challenge the modern world has never seen before and is overwhelming the capacities of healthcare systems worldwide. Patients with cardiovascular diseases, heart failure in particular, and cardiovascular risk factors seem to be at a very high risk if affected by COVID-19 - and vice versa there are more and more reports of cardiac manifestations with the viral disease. Aim: The purpose of the study is to characterise the clinical course of adult inpatients with COVID-19 and concomitant cardiovascular affection in a worldwide, multicentre PCHF registry. Methods: Retrospective and prospective data analysis. Data on demographic, clinical, selected laboratory, electrocardiography and echocardiography parameters, treatment and outcome will be collected. The principal investigator provides dedicated electronic case report form. The primary outcome is in-hospital mortality. The secondary endpoints will be ICU length of stay, hospital length of stay, the need and duration of invasive mechanical ventilation, cardiovascular hospitalisation after 3 and 6 months from index hospitalisation, all-cause and cardiovascular mortality after 3 and 6 months from index hospitalisation.

    NCT04390555
    Conditions
    1. COVID-19
    2. Cardiovascular Diseases
    3. Cardiovascular Risk Factor
    4. Heart Failure
    MeSH:Heart Failure Cardiovascular Diseases
    HPO:Abnormal left ventricular function Abnormality of the cardiovascular system Congestive heart failure Right ventricular failure

    Primary Outcomes

    Description: All-cause and cardiovascular mortality during index hospitalization.

    Measure: In-hospital mortality.

    Time: Hospitalization period, assessed up to 30 days

    Secondary Outcomes

    Description: The duration of hospitalization on the intensive care unit.

    Measure: The length of stay in the intensive care unit.

    Time: Hospitalization period in the ICU, assessed up to 30 days

    Description: The total length of stay in the hospital.

    Measure: The duration of hospitalization.

    Time: Hospitalization period, assessed up to 30 days

    Measure: The need and duration of invasive mechanical ventilation.

    Time: Hospitalization period, assessed up to 30 days

    Measure: Hospitalization for cardiovascular causes or cardiovascular deaths within 3 months after hospitalization.

    Time: 3 months

    Measure: Hospitalization for cardiovascular causes or cardiovascular deaths within 6 months after hospitalization.

    Time: 6 months
    17 Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial)

    Most patients undergoing a cardiovascular procedure need an ICU-bed during the hospitalization and therefore it is possible that for the unforeseen future, because of the Covid-19 crisis, many patients will stay on the waiting list for many months to come. There are some studies showing an increased mortality associated with an increased waiting time for the patients on the waiting list for an elective cardiac surgery. However, there is no data on the evolution of the morbidity, the quality of life and the symptomatology of the patients waiting for an elective operation. Also it is not clear whether the period of waiting for an elective cardiovascular operation would impact the morbidity or the mortality of the planned operation at later stage. Furthermore, there is a plethora of studies on risk factors associated with the perioperative morbidity and mortality in general. Therefore, the rationale of the current study is to evaluate whether Digital Cardiac Counseling (DCC) would improve outcomes of the patients waiting for an elective cardiac operation. At the DCC platform, there will be assessments of cardiovascular symptoms, Covid-19 prevention for cardiovascular patients, smoking cessation, anxiety relief, exercise stimulation, pulmonary rehabilitation and diet adjustments. This will be done by means of questionnaires and E-consults.

    NCT04393636
    Conditions
    1. Cardiovascular Diseases
    2. Cardiovascular Risk Factor
    Interventions
    1. Other: Digital cardiac Counseling
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention

    Measure: MACEs

    Time: Cumulative incidence (from inclusion) at 1 year postoperatively

    Secondary Outcomes

    Description: all-cause mortality

    Measure: Mortality

    Time: Before the scheduled date of the operation, at 30 days, in-hospital (at 30 days or during the same hospitalization for the planned procedure), at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

    Description: Mortality caused by cardiovascular disease

    Measure: Cardiovascular-related mortality

    Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

    Description: Mortality caused by Covid-19 infection and/or related complications

    Measure: Covid-19 related mortality

    Time: Before the scheduled date of the operation, at one-year postoperatively and cumulative from inclusion at 1-year postoperatively

    Description: Measured using SF (Short Form) 36 Health Survey

    Measure: Health-related quality of life

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

    Description: New York Heart Association Functional Classification

    Measure: NYHA Functional classification

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

    Description: Grading of angina pectoris

    Measure: CCS (Canadian Cardiovascular Society grading of angina pectoris)

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

    Description: Major Adverse Cardiovascular Events defined as Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for heart failure and/or fo earlier planned intervention

    Measure: MACEs

    Time: during waiting time measured before the scheduled date of the operation, at 1-year postoperatively

    Description: Respiratory failure, pneumonia, septicemia, renal failure, myocardial infarction, stroke, atrial fibrillation, pacemaker implantation, re-operation, delirium, wound infection, urinary tract infection and pressure ulcers

    Measure: Perioperative complications

    Time: during waiting time measured before the scheduled date of the operation, at 30 days postoperatively and at 90 days postoperatively

    Description: from surgery until discharge in days

    Measure: Hospital length of stay

    Time: from the admission to the hospital untill discharge from the hospital, assessed up to 12 months

    Description: measured in hours from arrival in ICU until extubation

    Measure: Time on mechanical ventilation

    Time: from the admission to the ICU untill discharge from the ICU, assessed up to 12 months

    Description: whether patient is active smoking

    Measure: Smoking status

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

    Description: Measured using HADS (Hospital Anxiety and Depression Scale) score

    Measure: Anxiety and Depression

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

    Description: the percentage of patients taking part in postoperative cardiac rehabilitation

    Measure: Participation in postoperative cardiac rehabilitation

    Time: postoperatively at 3 months, at 6 months and at 12 months

    Description: Percentage BMI<20 or BMI>30

    Measure: Body-Mass Index (BMI)

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

    Description: Unplanned visits to emergency department

    Measure: Number of participants with unplanned visits

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months

    Description: Total costs of the whole treatment process

    Measure: Healthcare costs

    Time: during waiting time measured before the procedure, at 3 months, at 6 months and at 12 months
    18 Association of Early Myocardial Injury With Major Adverse Outcomes in Patients With COVID-19

    The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.

    NCT04397939
    Conditions
    1. COVID-19
    2. Myocardial Reperfusion Injury
    3. Cardiovascular Diseases
    MeSH:Cardiovascular Diseases Reperfusion Injury Myocardial Reperfusion Injury Wounds and Injuries
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Number of death during hospitalization

    Measure: Number of In-Hospital Death

    Time: During hospitalization, average 2-3 weeks

    Secondary Outcomes

    Description: Length of stay in the hospital

    Measure: Length of Stay

    Time: During hospitalization, average 2-3 weeks

    Description: Successful treatment will be defined by two consecutive negative tests for COVID-19

    Measure: Number of Successful Treatment

    Time: During hospitalization, average 2-3 weeks
    19 STATIN THERAPY AND COVID-19 INFECTION (STACOV PROJECT)

    Considering that simvastatin, and probably statins in general, interfere with SARS-cov-2 cellular uptake and some inflammatory pathways activated by the virus, those patients on statin therapy should be less vulnerable to infection and their clinical course and prognosis should be better than that in individuals not on statin therapy.

    NCT04407273
    Conditions
    1. COVID
    2. Statin
    3. Cardiovascular Diseases
    Interventions
    1. Drug: observational
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Assess the difference in the WHO SARS-cov-2 scale of severity (9 steps) achieved by Covid-19 infected patients, admitted in the hospital, with and without background statin therapy comparable in age and gender distribution

    Measure: SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy

    Time: at the time of admission
    20 Multi-modality Imaging & Immunophenotyping of COVID-19 Related Myocardial Injury

    Cardiac Troponin elevation is associated with adverse prognosis in COVID-19. The MIIC-MI study aims to investigate mechanisms of cardiac injury in COVID-19 using multi-modality imaging and immunophenotyping to better understand the link with adverse patient outcomes.

    NCT04412369
    Conditions
    1. COVID19
    2. Cardiovascular Diseases
    Interventions
    1. Diagnostic Test: Non-invasive cardiac imaging
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Measure: Number of participants with a diagnosis of COVID-19 related myocarditis, Type 1 or 2 myocardial infarction and/or other mechanism of cardiac injury confirmed by multi-modality imaging.

    Time: Baseline

    Secondary Outcomes

    Measure: Comparison of a panel of inflammatory cytokines and immune cell profiles in patients categorized by cardiac diagnosis after imaging

    Time: Baseline

    Measure: Comparison of a panel of blood coagulation markers in patients categorized by cardiac diagnosis after imaging

    Time: Baseline
    21 Cardiac Involvement in Coronavirus (SARS-Cov-2) Infected Health Care Workers: The CCC Study

    The study will analyze the prevalence of cardiac involvement of health care workers from the University Hospital of Salamanca (HUSA) who have overcome SARS-CoV-2 infection. Participants will undergo a clinical evaluation, electrocardiogram (EKG), cardiac magnetic resonance (CMR) and blood analysis including NT-proBNP, troponin, cellular and humoral immunity and genetics.

    NCT04413071
    Conditions
    1. SARS-CoV 2
    2. COVID-19
    3. Coronavirus
    4. Cardiac Magnetic Resonance
    5. Myocarditis
    6. Cardiac Anomaly
    Interventions
    1. Other: Passed infection of SARS-CoV-2
    MeSH:Coronavirus Infections Myocarditis Heart Defects, Congenital Cardiovascular Abnormalities
    HPO:Abnormal heart morphology Abnormality of the cardiovascular system Myocarditis

    Primary Outcomes

    Description: Prevalence of myocardial damage suggestive of myocarditis assessed by cardiac magnetic resonance

    Measure: Myocarditis

    Time: up to 3 months

    Description: Prevalence of pericarditis assessed by clinical criteria

    Measure: Pericarditis

    Time: up to 3 months

    Secondary Outcomes

    Description: Prevalence of atrial fibrillation on EKG

    Measure: Atrial fibrillation

    Time: up to 3 months

    Description: Prevalence of ischemic heart disease assessed by cardiac magnetic resonance

    Measure: Ischemic heart disease

    Time: up to 3 months

    Description: Prevalence of dilatation of right heart chambers assessed by cardiac magnetic resonance

    Measure: Dilatation of right heart chambers

    Time: up to 3 months

    Description: Prevalence of valvular heart disease assessed by cardiac magnetic resonance

    Measure: Valvular hear disease

    Time: up to 3 months

    Description: Prevalence of prolonged QT interval on EKG

    Measure: Rhythm disorders

    Time: up to 3 months
    22 Qatar Cardiovascular COVID-19 Registry

    The novel coronavirus, severe acute respiratory syndrome coronavirus 2, that causes coronavirus disease 2019 (COVID -19), is highly contagious in the community and has resulted in a global pandemic. This infection has a special implication on the patient who complains from cardiac disease or acute cardiovascular condition and may result in cardiovascular complications such as myocardial infarction. For this end, we target to study this group of patient, who has a cardiac disease with COVID-19 in Qatar, in addition, the acute myocardial infarction with COVID-19 from the Gulf countries and collect all the related data to come with a comprehensive view about those patients.

    NCT04430374
    Conditions
    1. Cardiovascular Diseases
    Interventions
    1. Other: No interverntion
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: The outcome of this registry will be: entire information about the patients who admitted with COVID-19 accompany with a cardiovascular condition in Qatar. Additionally, a comparison will be conducted between the cardiac patient who admitted over the period February to December to December 2020 and the same category of patients over the same period of 2019 in Qatar to figure out the reason behind the dropping of the number of the patient. A multicenter data from the Gulf countries for Acute MI patients infected with COVID-19. A comparison between our patients (either in Qatar only or the entire Gulf) populations and the outcome of other international registries such as the NACMI (US registry)

    Measure: The impact of COVID-19 on cardiovascular patient

    Time: 2 month from starting date
    23 WHF COVID-19 and Cardiovascular Disease Survey

    A global study for a better understanding of the cardiovascular conditions that increase the risk of developing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients with COVID-19.

    NCT04475471
    Conditions
    1. COVID-19
    2. Cardiovascular Diseases
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: MACE is defined as the presence of any of the following CVD conditions: myocarditis, arrhythmia, heart failure [including Left ventricular ejection fraction], acute coronary event, as per the hospital admission and discharge records. Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

    Measure: Assessment of the patients for major adverse cardiovascular events (MACE)

    Time: Outcome will be assessed at discharge and 30-day follow-up visit from the hospital admission date.

    Description: Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

    Measure: Assessment of the patients for Pulmonary outcomes including Pulmonary embolism, pneumonia, acute respiratory distress syndrome, need of intensive care - number of days in ICU or ICCU, need of ventilator]

    Time: at discharge and 30-day follow-up visits from the hospital admission date.

    Description: Data will be collected at each site by local investigators and sent to the coordinating center. Only data outlined on the entry and outcome forms will be collected.

    Measure: Assessment of the patients for Neurological Outcomes including stroke and Transient Ischemic Attack (TIA)

    Time: at discharge and 30-day follow-up visits from the hospital admission date.

    Description: Specific causes of death to be evaluated using CRF including sudden cardiac death, death due to Myocardial infarction, Death due to heart failure, death due to stroke

    Measure: All cause deaths

    Time: any time during the hospital admission and at 30-day follow-up.
    24 Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients

    Non-commercial depersonalized multi-centered registry study on analysis of chronic non-infectious diseases dynamics after SARS-CoV-2 infection in adults.

    NCT04492384
    Conditions
    1. Covid19
    2. SARS-CoV-2 Infection
    3. Pneumonia
    4. Copd
    5. CKD
    6. Cardiac Event
    7. Overweight and Obesity
    8. Cardiovascular Diseases
    9. Diabetes
    10. Hypertension
    11. Coronary Heart Disease
    Interventions
    1. Other: non-interventional
    MeSH:Infection Communicable Diseases Cardiovascular Diseases Heart Diseases Coronary Disease Overweight Noncommunicable Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: percentage of patients with non-infectious diseases relating to overall number of patients registered in study

    Measure: rate of non-infectious diseases

    Time: 12 month since a moment of request of medical help

    Description: correlation between number of patients with COVID-19 of various severity and number of pre-existing conditions and their severity among these groups

    Measure: severity of COVID-19 depending on pre-existing diseases

    Time: 12 month since a moment of request of medical help

    Description: Registration of disability or change of disability status

    Measure: disability registration / change of disability status

    Time: 12 month since a moment of request of medical help

    Description: rate of deaths among registered participants

    Measure: rate of letal outcomes

    Time: 12 month since a moment of request of medical help

    Description: correlation between number of deaths and pre-existing diseases

    Measure: rate of letal outcomes depending on pre-existing disease

    Time: 12 month since a moment of request of medical help
    25 Development of a Dysphagia Risk Stratification Tool and Clinical Bedside Screening Tool in Cardiovascular Surgical Patients

    The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing cardiovascular surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.

    NCT04496986
    Conditions
    1. Cardiovascular Diseases
    Interventions
    1. Procedure: Fiberoptic Endoscopic Evaluation of Swallowing
    MeSH:Deglutition Disorders Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system Dysphagia Oral-pharyngeal dysphagia

    Primary Outcomes

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

    Measure: Penetration Aspiration Scale

    Time: Baseline (Prior to surgery)

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

    Measure: Penetration Aspiration Scale

    Time: Follow-up - Within 72 hours following extubation from surgery

    Secondary Outcomes

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

    Measure: Yale Residue Severity Rating Scale

    Time: Baseline (Prior to surgery)

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

    Measure: Yale Residue Severity Rating Scale

    Time: Follow-up - Within 72 hours following extubation from surgery

    Other Outcomes

    Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

    Measure: Vocal Fold Mobility Impairment

    Time: Baseline (Prior to surgery)

    Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

    Measure: Vocal Fold Mobility Impairment

    Time: Follow-up - Within 72 hours following extubation from surgery
    26 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE)

    MITIGATE is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).

    NCT04505098
    Conditions
    1. Covid19
    2. Atherosclerosis
    3. Cardiovascular Diseases
    4. Upper Respiratory Tract Infections
    Interventions
    1. Drug: Icosapent ethyl
    MeSH:Respiratory Tract Infections Cardiovascular Diseases Atherosclerosis
    HPO:Abnormality of the cardiovascular system Atherosclerosis Respiratory tract infection Type IV atherosclerotic lesion

    Primary Outcomes

    Description: Confirmed viral URIs (i.e., including recurrent events) (i.e., COVID-19, influenza, and other known viral respiratory pathogens) based on laboratory testing (i.e., FDA or locally-approved testing modalities) with an oxygen saturation <94% on room air and/or requiring any form of supplemental oxygen.

    Measure: Percentage of patients with moderate or severe confirmed viral URIs

    Time: 0-12 months

    Description: At any point in time based on a 7-point ordinal scale (i.e., 1 = death, 2 = mechanically ventilated/extracorporeal membrane oxygenation, 3 = high flow supplemental oxygen, 4 = low flow supplemental oxygen, 5 = hospitalized with no supplemental oxygen requirements, 6 = urgent care or emergency department visit not leading to hospitalization, and 7 = no relevant clinical encounters)

    Measure: Worst clinical status due to a confirmed viral URI

    Time: 0-12 months

    Other Outcomes

    Measure: Percentage of participants who die due to any cause

    Time: 0-12 months

    Description: Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke

    Measure: Percentage of participants experiencing a major adverse cardiovascular event

    Time: 0-12 months

    Description: Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)

    Measure: Percentage of participants experiencing an expanded major adverse cardiovascular event

    Time: 0-12 months

    Measure: Percentage of participants who are hospitalized for heart failure

    Time: 0-12 months

    Measure: Percentage of participants who are hospitalized for any reason

    Time: 0-12 months

    Measure: Percentage of participants who have an emergency department visit for any reason

    Time: 0-12 months
    27 Investigating the Association Between Smoking Status and COVID-19 Outcomes: Collecting Data From Health Systems Affiliated With the National Cancer Institute's Cancer Center Cessation Initiative (C3I)

    This cohort study will obtain electronic health record (EHR) de-identified data from 21 health systems affiliated with the Cancer Center Cessation Initiative (C3I) network or health systems with large numbers of COVID-19 patients to explore whether smoking status, cancer history, and other risk factors among patients diagnosed with COVID-19 are associated with mortality and/or COVID-19 disease severity/complications. Each site will provide de-identified data from their health system EHR on a monthly basis that includes all patients identified as having COVID-19 at some point in the interval from February 1, 2020, through December 31, 2020.

    NCT04506528
    Conditions
    1. Covid19
    2. Cancer
    3. Nicotine Dependence
    4. Pulmonary Disease
    5. Cardiovascular Diseases
    6. Immunosuppression Disorders
    MeSH:Cardiovascular Diseases Tobacco Use Disorder
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Death resulting from COVID-19 illness in inpatients vs discharge from hospital (binary outcome)

    Measure: Mortality due to COVID-19

    Time: February 1, 2020, through December 31, 2020

    Description: COVID-19 severity as measured by intubation for respiratory support (i.e., patient required intubation during hospitalization) - binary variable

    Measure: COVID-19 Severity

    Time: February 1, 2020, through December 31, 2020
    28 A Survey to Assess Effects of the Covid-19 Pandemic on Symptomatology, Treatment and Medical Care for Cardiovascular Patients

    The design included 152 patients with confirmed heart failure (HF) evaluated in two different periods of time: a baseline before the outbreak, and other during the outbreak of which 76 patients were randomized in each group. A care and follow-up guide was used as an instrument through a face-to-face survey (baseline group) and telemedicine (group outbreak). The primary outcome was the comparison of functional class modification observed in patients

    NCT04508920
    Conditions
    1. Cardiovascular Diseases
    2. Heart Failure
    Interventions
    1. Other: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: NYHA class modification in the last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). NYHA Scale: Minimum: 1 to maximum :4

    Measure: NYHA class deterioration

    Time: 1 year

    Secondary Outcomes

    Description: physiological parameter to worsening of shortness of breath perception, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021).Dichotomic scale presence or absence

    Measure: Dyspnea deterioration

    Time: 1 year

    Description: Physiological parameter to worsening of dyspnea that suddenly occurs to decubitus, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.

    Measure: Paroxysmal nocturnal dyspnea deterioration

    Time: 1 year

    Description: Physiological parameter to worsening of quantification of swollen ankles in both pelvic limbs, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence

    Measure: Edema

    Time: 1 year

    Description: a perceived limitation on walking more 500 meters, in last four weeks. Basal and follow-up measures: Basal on June 2020. Follow up: every three months and a year (June 2021). Dichotomic scale presence or absence.

    Measure: Daily activities In the last four weeks? Please, mention if you a perceived limitation on : Walking deterioration

    Time: 1 year
    29 Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial

    Coronavirus disease (COVID-19) related pneumonia significantly impact patients with underlying cardiovascular (CV) conditions. Animal studies suggest that drugs commonly used to treated CV diseases may increase the ability of COVID-19 to infect cells. The RAAS-COVID-19 trial aims to assess whether temporarily holding these CV drugs in patients who are admitted with COVID-19, versus continuing them, in patients admitted with COVID-19 can impact short term outcomes.

    NCT04508985
    Conditions
    1. COVID-19
    2. Cardiovascular Diseases
    Interventions
    1. Other: Temporarily holding the RAAS inhibitor [intervention]
    2. Other: RAAS inhibitor [continued standard of care]
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: The primary end point is a global rank score which is applied to all participants. The global rank sum is based on the following endpoints (and corresponding score): Death (7); Transfer to ICU for Invasive ventilation (6); Transfer to ICU for other indication (5); Non-fatal MACE (Any of the following - MI, Stroke, Acute HF, new onset Afib) (4); Length of stay > 4 days (3); Development of acute kidney injury (>40% decline in eGFR or doubling of serum Cr) (2); Urgent intravenous treatment for high blood pressure/hypertensive crisis (2); >30% Increase in baseline high sensitivity troponin (1); >30% increase in baseline BNP (1); Increase in baseline CRP to 48 hours >30%(1); Lymphocyte count drop >30% (1). The primary endpoint will be assessed from baseline to day 7 (or day of discharge if occurs before day 7). Participants will receive a weighted score depending on the events experienced. The global rank sum score will then be averaged and compared between treatment arms.

    Measure: Global rank score

    Time: Baseline - day 7
    30 Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff

    Patients are part of a family network. When any person in a family becomes critically unwell and requires the assistance of an Intensive Care Unit (ICU), this has an impact on all members of that family. COVID-19 changed visiting for all patients in hospitals across Scotland. It is not known what effect these restrictions will have on patients' recovery, nor do we understand the impact it may have on their relatives or staff caring for them. This study will look at the implications of the visiting restrictions as a consequence of the COVID-19 pandemic upon patients without COVID-19 who are in the cardiothoracic ICU. It will also explore the impact of these restrictions on them, their relatives and staff. This study will be carried out within a single specialised intensive care unit in Scotland using mixed methods. The first arm of this study will use retrospective data that is routinely collected in normal clinical practice. The investigators will compare patient outcomes prior to COVID-19 with outcomes following the implementation of COVID-19 visiting restrictions. The aim is to establish if the restrictions on visiting has an impact on the duration of delirium. Delirium is an acute mental confusion and is associated with longer hospital stays and worse outcomes in this patient group. The second arm of this study involves semi-structured interviews with patients, relatives and staff that will allow deeper exploration of the issues around current visiting policy. The interviews will last approximately 1 hour and will address these issues. They will then be transcribed word for word and analysed using grounded theory, meaning the theories will develop from the data as it is analysed.

    NCT04538469
    Conditions
    1. Cardiovascular Diseases
    2. Delirium
    3. Critical Illness
    4. Intensive Care Unit Delirium
    5. Thoracic Diseases
    6. Respiratory Failure
    7. Cardiac Disease
    8. Cardiac Failure
    Interventions
    1. Other: COVID visitation restrictions
    MeSH:Respiratory Insufficiency Thoracic Diseases Delirium Cardiovascular Diseases Heart Diseases Heart Failure Critical Illness
    HPO:Abnormal left ventricular function Abnormality of the cardiovascular system Congestive heart failure Right ventricular failure

    Primary Outcomes

    Description: Number of days patient found to have delirium using the Confusion Assessment Method for the ICU (CAM-ICU)

    Measure: Duration of delirium

    Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.

    Secondary Outcomes

    Description: CAM-ICU

    Measure: Incidence of delirium

    Time: From the date of admission to the Intensive Care Unit (ICU) until discharge from the ICU or death, whichever came first, up to 12 months.

    Description: Days

    Measure: Length of critical care stay

    Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

    Description: Days

    Measure: Length of hospital stay

    Time: From the date of admission to the hospital until discharge from the hospital or death, whichever came first, up to 12 months.

    Measure: Doses of specified drugs during ICU admission

    Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

    Description: Days

    Measure: Length of time ventilated

    Time: From the date of admission to the ICU until discharge from the ICU or death, whichever came first, up to 12 months.

    Measure: Mortality

    Time: 6 months

    Other Outcomes

    Description: Semi structured interviews

    Measure: Exploring the experiences of patients, relatives and staff of the visitation restrictions during the COVID-19 pandemic

    Time: 18 months
    31 Evaluation of the Potential Benefit of Renin-angiotensin System Inhibitors (RASi, ACEi/ARB) in High-risk Patients With COVID-19. The COVID-RASi Trial

    The COVID-RASi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in older COVID-19 patients who are at high-risk for cardiovascular disease. The purpose of this study is to determine if renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), has a beneficial effect in high-risk older patients with COVID-19 infections, by reducing ICU admission, ventilator requirement or death. We would also like to determine if there are differences between ACEi and ARB therapeutic treatments.

    NCT04591210
    Conditions
    1. COVID-19
    2. Cardiovascular Diseases
    Interventions
    1. Drug: Angiotensin converting enzyme inhibitor
    2. Drug: Angiotensin II Receptor Blockers
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Within first 28 days post randomization

    Measure: Death

    Time: 28 days

    Description: Within first 28 days post randomization

    Measure: Mechanical ventilation

    Time: 28 days

    Description: Within first 28 days post randomization

    Measure: ICU admission

    Time: 28 days

    Description: Within first 28 days post randomization

    Measure: Major Adverse Cardiac Events (MACE)

    Time: 28 days

    Secondary Outcomes

    Measure: Days alive and out of hospital

    Time: 30 days

    Measure: Days alive and out of hospital

    Time: 180 days

    Measure: Cardiovascular mortality

    Time: 1 year

    Measure: All cause hospitalization

    Time: 1 year

    Measure: Percent of patients require intensive care

    Time: 1 year

    Measure: Percent of patients requiring ventilation

    Time: 1 year

    Measure: Percent of patients requiring dialysis

    Time: 1 year
    32 Cardiovascular Clinical Features and Cardiovascular Therapies in the Development, Progression and Outcome of Patients With SARS-Cov-2 Related Pneumonia

    The CVP-COVID19 registry is both a retrospective and prospective study design in order to identify predictors of cardiovascular disease progression and mortality for COVID-19. The registry enrolls consecutive patients with positive microbiological tests for SARS-CoV-2 admitted to an academic hospital in northern Italy for worsening of COVID-19 symptoms. The study does not test any new diagnostic or therapeutic approach. Patients are treated according to good clinical practice. Patients characteristics, including medical history (with particular attention to cardiovascular and pneumological risk factors), features of physical examination, results laboratory and radiological tests and treatments (pre- and in-hospital) are related with patient outcome. Logistic analysis (univariate, multivariate and propensity) are performed in order to identify factors associated with disease progression. Primary endpoint: mortality.

    NCT04606732
    Conditions
    1. Covid19
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: All causes mortality

    Measure: Mortality

    Time: 30 days

    Description: All causes mortality

    Measure: Mortality

    Time: 6 months

    Description: All causes mortality

    Measure: Mortality

    Time: 1 year
    33 Innovative Support for Patients With SARS-COV2 Infections (COVID-19) Registry (INSPIRE)

    This study will use a digital platform to longitudinally track comprehensive information including patient self-report as well as data that describe the process and outcome of care in the electronic medical record (EMR) of a large representative sample of patients under investigation for SARSCOV2. The objective is to generate knowledge rapidly using digital tools and collaborative sciences to produce real-time data, analysis, and reporting compared to more traditional approaches. An additional goal is to promote an open science approach whereby scientists, with proper approvals and in line with the permissions granted by the participants, have the opportunity to work with data in ways that protects individual privacy but promotes rapid dissemination and implementation of knowledge.

    NCT04610515
    Conditions
    1. Covid19
    2. ME/CFS
    3. SARS COV2
    4. Novel Coronavirus Infection
    5. Neurocognitive Disorders
    6. Cardiovascular Diseases
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Cardiovascular Diseases Neurocognitive Disorders
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: determine the risk of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in those with symptoms of SARSCOV2 infection with vs. without a positive confirmatory test.

    Measure: Incident myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

    Time: 18 months post enrollment

    Secondary Outcomes

    Description: Count of ambulatory care and/or ED visits post enrollment as obtained from the EMR

    Measure: Ambulatory care and/or ED visits post enrollment

    Time: 18 months post enrollment

    Description: Count of hospitalizations post enrollment as obtained from the EMR

    Measure: Hospitalizations post enrollment

    Time: 18 months post enrollment

    Description: death during hospital admission as determined by data from the EMR

    Measure: Death during hospital admission

    Time: 18 months post enrollment

    Description: Hospital-free survival as determined by data from the EMR

    Measure: Hospital-free survival

    Time: 18 months post enrollment

    Description: ICU-free survival as determined by data from the EMR

    Measure: ICU-free survival

    Time: 18 months post enrollment
    34 Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial

    Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.

    NCT04615949
    Conditions
    1. COVID-19
    2. Cardiovascular Diseases
    3. Cardiovascular Risk Factor
    Interventions
    1. Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC
    2. Drug: Placebo
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: proportions of patients not surviving

    Measure: All-cause mortality

    Time: 28 days post randomization

    Description: Proportions of patients needing ICU admission and/or ventilatory support

    Measure: Requirement for ICU admission and/or ventilatory support

    Time: 28 days post randomization

    Description: HF, AMI, myocarditis, new sustained arrhythmia or stroke

    Measure: CV complications

    Time: 28 days

    HPO Nodes


    HP:0001626: Abnormality of the cardiovascular system
    Genes 4365
    NR2E3 ND4 MMUT EDNRB NDUFS6 TMEM94 LPIN2 COG4 VEGFC PGM3 GATA1 PDE11A KIAA1549 SLMAP LBR CD247 RHBDF2 AGK ABCD3 SEMA5A GP1BB HS6ST1 FANCC SEC61A1 SEC24C PROM1 CALM1 TRNL1 ANK2 NELFA HPS3 STING1 GDF1 MMP14 APOE PEX11B POLR1A OFD1 ABCA12 FGF20 ABCG8 CCDC141 NSD2 CYTB HGD KRAS NKX2-5 JUP KCNH2 TRIP13 FEZF1 PERP IKBKG BTD LDB3 GDF1 RAD51 ERCC4 FGB NDP SLC25A4 ASXL1 CTLA4 ABCC9 LBR FLT4 KCNJ2 SEC31A ATP6 USH2A FLNC GATA4 MYH6 PLEC NSD1 FHL1 GLB1 TSC2 LMNA CAVIN1 TNFRSF4 FLT4 GUSB AIP EVC C12ORF57 RET RNU4ATAC PPP2R1A TPM3 XYLT2 COQ2 FBLN5 HBA1 LZTFL1 ACP5 NUP188 IL7 MAP2K1 ROBO4 MYLK PUF60 FKRP TPM2 TTR TSFM TMEM67 FGFR2 SPOP IGH KDSR DNAJC21 LETM1 ACTN2 POMGNT1 PTDSS1 MYF6 CD70 SOS1 ATP6V1A GJB6 NPPA ACADM GATB TERF2IP GLI3 G6PD HNF4A MGMT COA6 RERE KLLN IFNG ARNT2 FANCM WT1 PDE11A FOXP3 USP45 MYCN UBR1 MYOT IARS1 ENG PLEKHM1 GJA1 GLI2 DNAJB13 PRKAG2 FLT1 INVS IDUA CCDC174 NOTCH3 HPGD HIBCH CAV1 IFNG HLA-DRB1 JAG1 ARL13B GFM2 HOXA13 COL4A1 GBE1 SALL4 CFHR1 TBXAS1 DDX58 TGIF1 MKS1 LACC1 DNAJB11 ND5 RPS19 H19-ICR BLOC1S3 CDON PRPF6 PLCB4 GPD1 SLC18A2 FGFR1 EVC2 NEDD4L BAP1 RPGR THPO MST1 LAMA2 HPS5 ADAMTSL2 PEX14 RAB23 NDUFA6 MYH7 ESR1 EDA VCP KCNE3 ZIC2 KMT2E HFE SDHD C2 ITGA2B TET2 CAV3 ALDH3A2 PEPD FGF8 RAF1 SHH XYLT2 PSMB4 SON HMBS TLL1 DTNBP1 ABCD4 FHL2 MMEL1 NODAL JAK2 HEPHL1 TAZ HAAO BUB1B ERAP1 ADAMTSL1 CSTA SMC1A ZNF148 LZTR1 MIB1 CLRN1 FMO3 TMEM231 PRTN3 PIGN CHRND TRNF LRP6 TDGF1 NDUFB11 COL1A1 SCARF2 PTPN22 UBE3B DPF2 ANKS6 DNM2 XK KRAS HEXB IDH2 MYH6 IRF5 HLA-DQB1 ERBB3 DUX4 TBX19 SIX3 IDH3B MTHFR FANCB TERT EPB42 TRNL1 ZEB2 ODAD1 NECTIN1 COX1 ARCN1 COL1A2 LDLRAP1 TP63 SMAD3 F13A1 CAV1 GJA1 VPS33B CASR WDR35 LIG4 LARP7 CCDC40 CUL7 DDRGK1 IL2RG PLOD1 HAND2 PRRX1 SACS SCN5A WT1 CD96 WT1 TGFB3 PRPF3 ACTA2 BBIP1 SLC4A1 HAMP LMNA GBA CYP11B1 SGCG IDUA TRNL1 CTSK KLF1 ABCC6 SIM1 SETD5 SAMD9L SF3B1 ESS2 NCF4 DRC1 FERMT1 TPI1 NFU1 NDUFS2 COX7B SCAPER DNAH5 SAMHD1 MAN2B1 KCNJ18 FXN AGXT ZMPSTE24 ALDH18A1 ACTL6A GFI1B D2HGDH EOGT GP9 CEP290 HCCS SMARCB1 PIGV GMPPB TRIM32 DNAAF4 HPS1 KIF15 ODAD4 SPECC1L TDGF1 PMM2 SGSH WAS SOX9 DCAF8 HAVCR2 ND5 CDKN2A ARX GNPTAB SEMA3E IL17F SCN10A LRRC8A SLC35A2 CCNO LMNA MYL2 SOX2 NKX2-5 NOS3 SETD1A NEXN BMPR2 CDK8 POMT1 ERGIC1 TMEM127 NCKAP1L CC2D2A JAK2 HNF1A BAP1 DKC1 CYBB COL1A1 PAFAH1B1 VHL SCN5A TTC7A FOXH1 NDUFAF5 TNNI3 SLC25A11 PAFAH1B1 ND1 ITGA8 GLMN MYD88 EIF4G1 ARF1 KCNJ5 SLC20A2 PRNP RRAS XPA GATA4 AKAP9 STRA6 SDHA FGF17 FANCC TRNW ARMC5 COA8 PSAP DHCR7 PTCH1 CALM3 MEN1 CLCNKB MAB21L1 PROK2 CKAP2L CC2D2A F7 BPTF COX10 MGME1 TKFC ADAM17 CRYAB PLAGL1 ABL1 NDUFS1 WASHC5 SMARCE1 INTU ERCC5 ACTN4 STAT3 DYNC2LI1 TRNV HGD HYMAI WNK4 LIFR SHH AEBP1 MEFV DNAI2 AKT1 ND4L NFIX NFKB2 DCDC2 PIGL TGFBR2 ATP6V1E1 XYLT1 CRELD1 PTPN11 DLST MYH7 FOXF1 SDHAF1 TGFBR3 GDF2 LARS2 GDNF RPS6KA3 PROKR2 APC2 TNFRSF1B CTNS SMARCC2 FGFR1 PQBP1 COX15 PPOX F10 PNP GLUL PKHD1 NKX2-5 HYLS1 CAV1 BLM ASCC1 MYH6 MEIS2 KCNJ11 TFRC IDH1 PEX6 RPS26 COL6A3 CIB1 SOS2 RPL18 DVL1 RHO TGFBR1 RPGRIP1L TRNK CEP120 EPB41 CYP7B1 FECH SF3B4 UBE2A CRYAB MNS1 FGFR2 MEOX1 VAMP7 LMNB1 GP1BA ARL6 JAK2 NDUFAF1 SRY CFC1 DNMT3A EPAS1 KCNQ1OT1 WNT10A TANGO2 GATA6 TNFSF4 DYRK1B GATA6 BSCL2 RUNX1 ATP5F1A AKR1D1 DHCR24 OFD1 ABCC9 USB1 TSHR HTRA1 THSD1 SMC1A SVBP GYG1 ALB F8 COL2A1 TFAP2B COL3A1 ABCG5 ALDOB DLL1 IFNGR1 SDHB TNFRSF11A CEP57 CASP10 PTPN22 RAB3GAP2 ABCA4 TERT POGZ F8 CA2 PIGP PEX11B NOTCH2 COL5A1 NRXN1 CD81 NODAL MYBPC3 ANKRD11 SDCCAG8 F13B PPARG NDUFA2 CSGALNACT1 SF3B4 STXBP1 BCOR HADHA SNCA DNMT3A ARL2BP DSP KIF11 WRN SLC37A4 GNAQ SCN9A AGXT EDNRA AVPR2 CCND1 RYR1 ATP6V0A2 XYLT2 MYL3 NBEAL2 ODAD4 CACNA1C FGF8 RIT1 RLIM GATA1 TFAP2B TMEM43 F9 MEF2A DISP1 CNGA3 GPC3 TCTN3 PRF1 ETV6 SLC29A3 CLCF1 NPHP3 TCF20 IL17RA CANT1 LMNA FREM2 RAG1 FRA16E LMNA LMNA CPLANE1 DLL1 EIF2AK3 AKT1 HSPG2 FAN1 G6PC NFIX MUC5B EWSR1 ZMYND10 ACTG2 SDHC DHODH SGCG PTCH1 CD79A ARL6 COL5A2 FIP1L1 PBX1 LRP5 SMARCA2 SOX9 RPGR SCO1 SPECC1L GINS1 GLRX5 TGFB2 PIK3CD PHOX2B BRAF ALAS2 TCTN1 SLURP1 EBP ECHS1 NF1 ARHGAP31 GATA4 IDH3B CDH2 CSNK2A1 GLI2 PROS1 ALMS1 PEX26 SIX3 FGFR2 ATRX TGFB2 FGF8 PSAP ACAD8 BCHE NPHP1 AP1S1 CHST14 POLG WDFY3 LRIG2 DCX NDP DNASE1 NIPBL POU1F1 CEP41 OPA1 ARMC9 TULP1 SDHA IFIH1 TWIST1 RNF135 GATAD1 ND3 MYRF ND1 BRCA2 APP IFIH1 ND5 FXN FOXE3 APP BRCA1 FIBP NXN PEX3 ATPAF2 CIZ1 EYA4 ALDOA ORAI1 MTAP CD19 COX1 CEP104 LMNA RAI1 GUSB LRP5 GNE NGLY1 TMCO1 SAMD9 SDHA F13A1 POMP GMPPB GUCA1B PKP2 NPHP4 HDAC8 TRAPPC11 ALDH18A1 PUF60 PTCH2 SMAD4 RANBP2 KIAA1549 MPL SCN5A OCLN THBD DOCK3 SUMF1 SNAI2 MYL2 PIK3CA CYTB FAH STAG2 POLR3A KRT83 SEC23B GATA6 FOXC1 MYSM1 SERPINC1 SARS2 GJA1 CDKN2A ABCC8 CPT2 CBS TET2 PRPH2 ZMPSTE24 SDCCAG8 NR3C2 TCF3 RPL11 NKX2-1 NDUFA4 ZMPSTE24 TCAP PACS1 ALG12 KMT2D RPL15 TGFB1 IGF2 CKAP2L CASR CCDC47 GGCX NOTCH1 RRAS2 PDE6H ADCY5 MYOZ2 HLA-DPA1 CHD7 RPGRIP1 RSPH3 GNAQ SELENON RYR1 CLPB PIGN ND3 SMC1A TGFBR1 IDH1 PADI4 CFH HSD3B2 TRNN SUFU MRPL3 FOXF1 KLRC4 COG7 B3GALT6 SMAD6 WWOX USP9X ATP2C1 PDCD10 PIGU KRT5 KCNJ2 NDUFAF6 CITED2 NLRP3 ESCO2 RPL5 ZFPM2 ELN JAK1 ZFPM2 NR2F2 FGF8 TKT WASHC5 HLA-B CTU2 SETD2 PNPLA2 ATP6V1B2 ARHGEF18 FBN1 JAG1 MEN1 BMPR1A KIAA0753 ATP6V0A2 ZNF423 STK4 GCH1 AKT3 PMS1 C8ORF37 CPN1 RHAG POGZ DSP NDUFS2 F12 JAK2 ATRX TTN BRAT1 FUCA1 CFH ADAR KCNE2 JAK2 NLRP3 CCDC103 CEP120 HBA1 AGK SMARCE1 ERCC5 CLCC1 GPD1L GUCY1A1 PRCD AGGF1 DOLK DCHS1 TRDN CALM1 FSCN2 FAM161A TNNI3K MRPS22 KRIT1 FGFR1 DMXL2 DNAH11 IL17RC FLNA FCGR2C NSMF NAA10 GNAS KDSR KIZ MKKS LDB3 DNAI1 AGTR1 ERCC2 BRF1 IGH LRRK2 GLI2 FGG SNRPB IL10 FZD2 QRSL1 SLC4A1 STEAP3 SLC26A2 OFD1 GJB3 PEX13 SCN9A MCTP2 ANK2 FGF8 PIK3R1 EP300 SCNN1B CASP8 KCNE5 EFTUD2 RP1L1 SCN1B PLVAP FOXH1 IMPG2 SDHAF1 DNAAF1 CDH23 TDGF1 IL2RA MAP3K7 COL4A4 FGA PDE3A USP8 REN AMER1 CC2D2A TERT GJB3 ZIC2 ARID1A WDR35 PRKAR1A PRDM16 RIT1 BGN WIPF1 GNA11 SF3B4 F2 NF2 SLC29A3 SLC19A3 FAS RNASEH2A DYNC2I1 TGIF1 FLNA DCLRE1C SMAD4 BBS1 PALB2 GTF2IRD1 CFI TET2 KDR FADD APOA1 COX7B AKT2 TAB2 PDX1 SLC39A4 MYLK SMC3 FKRP SLC29A3 PLIN1 FLNA FOXE1 SPARC GBA GATA3 COL6A2 PCARE KLF13 BANF1 ESCO2 MYH11 SCN4A FBN2 DCAF17 RTEL1 RPGRIP1L LIPC SBDS KRT9 HMCN1 CACNA1D FANCE KRAS TLR4 ETHE1 GPD1L PEX19 XPR1 TRNC FANCA ODAD2 NEK9 FBN1 IFNG SDHD ANTXR1 ELANE CXCR4 COL4A3 CENPE BBS4 DMD C4A IFT88 UROS KANSL1 MMP1 FMR1 KRT16 F13A1 PCCB TSC2 NR3C1 PRPF8 SETBP1 USB1 LAMP2 TET2 BPGM MVK NKX2-1 SLC17A5 CTCF PNKP DDX3X RRM2B GFI1 RNF113A CLIC2 MAF DDC ALG9 KAT8 TMEM237 NEBL STK11 IL10 SLC7A7 MED12 CDKN2B LONP1 ERBB3 RET JAK3 PEX10 OTX2 SYNE2 AICDA GLB1 GTF2H5 ZFPM2 PLOD1 RPS28 PRDM16 COL3A1 IKBKG ITGA3 ITPA CIITA GBA DOCK6 ACTC1 JAK2 KIT CDC45 CARD11 GALE CFAP298 PEX5 DCC COL7A1 TRPM4 WNT5A SHANK3 MTHFR TRAF7 MAP2K2 LIMK1 NRAS HLA-DRB1 EXT2 LMNA FBN1 SOS2 HBB PSAT1 FANCI MITF TNNI3 SALL1 PAX8 TARS1 NSD2 DNAAF3 DAXX DYNC2LI1 NLRP3 NPHP3 NPC1 HJV TNFRSF1A HLA-DPB1 SYNE2 DSG4 RINT1 LZTR1 SLC25A11 COL1A2 TRAF3IP1 TRPM4 MPIG6B VHL POMK GANAB TCAP NLRC4 EIF2AK4 RPSA GPR35 POMT2 CLRN1 LRP2 STAT5B FBXW11 NLRP3 CHRNA7 KRAS FCGR2A KIAA1109 CNGB3 SELENOI MYOC ATP8B1 CYBA ERCC6 SF3B1 PLN GNA14 FOXH1 MDM2 CAT TCF4 THOC6 PET100 ACTG1 ITGB3 NOTCH2NLC IL12RB1 CYP11B2 ATP6V0A2 CACNA1D PITX2 PKLR TCOF1 GAS1 ERCC4 PLN STAG2 TRNH KIF1B PTPN22 SPTA1 POMGNT1 HGSNAT F10 SLC2A1 ERCC3 IDUA HLA-B COL5A2 GM2A NDUFV2 TWIST1 MIPEP EFEMP2 NCF1 ADA2 RPS15A HESX1 KMT2A F2 IL2RB ERCC4 DISP1 CSRP3 ATP6AP2 BCR RBM10 PEX1 FGFR2 WNT3 COL1A1 AP1B1 GATA1 NR5A1 ACTA1 HCRT PDGFRB FASLG SMAD4 DMPK CYSLTR2 ROM1 CCDC103 CACNA2D1 HBA2 PEX5 ATAD3A FGF8 CCDC39 NEU1 COQ2 POU3F4 LMNA RPS15A NKX2-5 HBA2 PSAP HSD11B2 GJB4 ITGB3 MDH2 CA4 RP9 BBS2 PITX2 KCNE3 PALB2 RAF1 KCNN4 LMBR1 CFB WDR11 PEX2 WAC ARL6IP6 GNAS PLEC FLNA TCIRG1 TP63 NF1 SON PIK3CA NKX2-5 LMNA CHD7 CUL3 NMNAT1 KCND3 SLC4A1 BCS1L CAPN5 CD55 TTC37 LONP1 SHOC2 GJA8 HTRA1 GPC6 ABCA3 STK36 LMNA OFD1 PALB2 TECRL HLA-A SURF1 FGFR2 FMR1 APOB TFAP2A AP3D1 ACTA2 DHPS PEX6 AGT ZMYND10 SOX18 TGM5 TPM2 REST ZIC2 SNRNP200 SC5D PTEN TBX22 CTCF PRRX1 RAC2 CTLA4 PLP1 MEGF8 FGFR2 ZIC2 TAF2 EFL1 TTC8 DDB2 B9D2 PEX16 EFEMP2 PTEN PCNT NEUROG3 CFHR1 PDSS2 PIK3R2 FGFR2 SPIB TGFB3 FANCB USH2A TNXB MYH7 PRPH2 SCNN1G UMPS ACVR2B TRAPPC4 XPNPEP2 PTCH1 LEMD3 CRLF1 TNFRSF13B MYH8 COL1A2 MYPN MCIDAS F2 GNAT2 YWHAE CYP11B2 IVNS1ABP NSUN2 CHRM3 COL1A2 SLC25A4 STIM1 DHCR7 KRAS TMC8 RBM10 DPH1 LYZ KDM6B FAM13A MFAP5 CWC27 TBX3 MRAS MAN2B1 KRAS KRAS SH2B1 ANO5 TUB CDH2 CYP27A1 CBS NODAL IFT122 ACAT1 RBM20 NDUFB3 ROR2 COL4A1 MUC5B USP8 LIPN RTTN CRPPA SMAD4 HBG1 MED25 CCND2 SELENON COG4 RREB1 JUP PROP1 CEP57 DLL4 SH3PXD2B DES CEP41 TBX1 CEP164 RNASEH1 ADCY5 ERMARD NRAS GJA1 GPIHBP1 ZNF408 COLGALT1 PTEN AMMECR1 SDHC ATM DPH1 SLC25A4 AKT1 CYP21A2 FLNA NR2F2 TBX5 GCDH ATP2C1 STAG2 MED13 GATA6 GALNS ACTC1 IDH2 UNG MRPS16 CTLA4 KAT6B SMAD4 CLCN7 POLA1 SCN2A HBG2 RPS7 TNNI3 MMP21 GLB1 SCN4B NDUFS3 PIGL AKAP9 WDPCP ADA2 COL4A1 KAT6B VANGL2 SCN3B ACTL6B EED GLI3 PLCG2 ADAMTSL4 FGFR1 BRIP1 ZNF513 KCNE1 ERCC3 PTPN11 TRPV3 PRKCD FBN1 RIN2 CD79B ALOX5AP TECRL ABHD5 CD46 RAI1 MYT1L GP6 COL3A1 MAP3K7 ARID2 HDAC8 SPATA5 KAT6A BCOR DGUOK CACNA1C DVL3 BCL10 ABCB4 TP63 HLCS TRPS1 NEU1 ACADL BMPR1A RSPO2 NADSYN1 POLG2 GDF6 MAX SOX2 TRIP11 ARID1B SLFN14 POLG2 GAA UBE3A FKTN SNTA1 FGG CSPP1 TERT GDF6 ARFGEF2 DES UBE2T GALNT3 CSRP3 KYNU HCCS KCNMB1 HMGA2 LMNA CPT2 TMPO TTC7A SLC25A24 SKI STAT3 NRAS TTC12 RPS24 INPP5E BPTF FLNA TFAP2A RPL35 SLC2A10 RPS17 SDHA CYP17A1 INPP5E NLRP3 CCDC40 ASAH1 POLR1A CTNND2 MYH3 MVK NOS3 BRAF ATRX KCNJ5 APRT PRPF31 PIEZO2 MED13L KCNQ1OT1 NDUFS8 DTNA CCM2 PHKA2 NKX2-5 GJA5 POU2AF1 SNAP29 PAFAH1B1 FOXH1 SLC40A1 SULT2B1 HADH MBTPS2 FLII FN1 NRL PDE6G RBP3 PHKG2 ARPC1B CDKL5 SMARCA4 SP110 HCN4 TCTN2 ITPR1 FANCA PMM2 RASA1 ROR2 COX3 CEP290 ALPL POLG STAT3 DNMT3B PEX26 MGP ABCC9 OTX2 DLL1 KCNE1 SHH COQ2 ABCA1 EP300 DDRGK1 CLIC2 ITGA7 SCN9A IRF2BP2 CCNQ TNNC1 RIN2 ADGRE2 ALKBH8 NF1 CPOX OTC DHCR24 ARID1B MAK RMRP LIPT1 NEK10 SGCA FGFR2 MICOS13 SOX5 NEXN SYNE1 BIN1 TGM1 PSTPIP1 COL7A1 FOXE3 EDN3 IGF2 H19-ICR B3GLCT TUBB MYCN TNFSF12 PIK3R1 RASA1 F5 SARDH GSN SH2B3 DSP KIAA0319L SLC52A2 CDKN1B LIPA TELO2 SSR4 GJC2 DACT1 TRPM4 GYG1 FIBP RBM8A ZIC2 CDC42 LRRC56 LMNA TNNT2 DNAI2 NONO FAT4 PPCS ERCC8 USP18 VWF SALL4 PQBP1 GBA GJB2 GATA4 PDE6B GATA4 MYH11 HFE EED CDON PROC STRADA TTR SLC26A2 BMP2 WWOX BVES C8ORF37 CALM3 TPM2 CITED2 PTEN DYNC2I2 COX3 SNRPB MTO1 DHX37 SLX4 LOX ACTA1 IRF8 XRCC4 TRIP13 CDC73 ODAD3 DNAAF2 MANBA CFTR SCNN1A PPP2R5D WARS2 CCDC39 PKD2 TNNT2 PRKCH SMAD9 RYR1 ELOVL4 JMJD1C TRNT1 VPS33A ODAD1 ZMIZ1 CREBBP DIS3L2 AGA SETX SGCD BAP1 COX2 SLC25A20 KIAA0586 GTF2I POT1 EFTUD2 ALG9 KIF3B TRDN LMNA ACTG1 ALX4 COX1 ACAD8 ATP6 TRPC6 LMNA LAMB2 ERCC4 GTPBP3 PDE6A HPS6 GATA1 OTUD6B COQ7 LRP5 BEST1 MPI CALR CCM2 HBB VPS33A GDF3 CYP11B2 OTC SEC23B RPE65 ANKRD26 TET2 SCNN1A RLBP1 EPG5 DSP POLR1C SIX3 KRT5 GLA MTHFR HBB RPL35A ND1 FGG SDHD MARS2 CYP26C1 ANTXR1 APOB HLA-B TRMT10C ATP6V1E1 TRNE UVSSA CPOX CDHR1 SLC20A2 RBCK1 TWNK AKAP9 APOC2 NDUFAF3 SAA1 HBA2 KCNQ2 TAF1A NBAS DBH SMAD6 TEK EXT2 ABCC6 FZD4 NKX2-6 RAG1 LIPT1 F8 BAP1 NCAPG2 YY1 LPL TMEM107 DUSP6 SLC25A3 AHI1 PRKACA PNPLA6 RHOH FGFR1 PLAGL1 SNCA CREBBP SCN5A MYH11 EVC2 LDB3 GBA PRDM5 GATA6 WFS1 ND4 NDP SLC25A26 GBA SLC19A2 ND1 NEXN RARB NDUFAF1 ATP7A F5 DCHS1 GJA1 APOE ELN GNAS MAF PLCG2 HLA-DQB1 HBB TCIRG1 RAF1 EXTL3 ATP11A ND6 PCCA TPI1 SOX10 KIT NPPA APP GNAI3 NKX2-5 VAC14 PDGFB BIN1 LIPA TGFBR2 SPTA1 NDUFS7 FOXJ1 NEK1 RPL10 SCNN1B ECE1 KIT ATP7A FSHR CYBC1 SEMA3A SMARCD1 PRKAR1A JAK3 CD109 SPTB PCGF2 LIG4 FERMT1 MYH7 LZTFL1 SGCD IRF5 PTCH1 CA2 SYNE1 NTRK1 CHRNA1 FGA RSPRY1 KCNJ8 FRAS1 ERCC6 RNASEH2B P2RY11 NEU1 GP1BA MYH7 BTNL2 NDUFA9 KIF23 ND2 HSPA9 PIGA MEIS2 CACNA1S DNAH11 GCLC ACVRL1 POMT1 AGTR1 DMD POLG MSL3 PLCB3 GP1BB CAV1 KCNH2 TPP2 FARSB UCP2 IRF6 SALL4 PACS1 GLI2 AHI1 SHOC2 FUZ MAP3K1 MYH6 SRP54 IGHM CRKL C1QBP IL10RA COX15 SLC12A3 DLL3 RPS26 FERMT3 LOX RBPJ RB1 ZBTB16 LCAT CYP11B1 GIGYF2 SFTPC HSD3B7 IL12A-AS1 RECQL4 SIK3 MKKS SFTPA2 ABCA1 BNC2 IFT172 LMX1B SDHB SCARB2 RNF6 PARS2 XYLT1 CALR GP1BA GLI1 CRELD1 FGFR3 FANCF RAF1 SFTPC MPL PRKCSH ODC1 ALG10B IARS2 GPC6 GJA1 BAZ1B BRAF METTL5 JAK2 ATP6 DNAAF3 WDR19 CALM2 EBP STOX1 ICOS CALM2 DCTN1 SIX3 FKRP TMEM231 DNASE1L3 TTN SPRY2 TMEM70 FASTKD2 KIAA0586 ATF6 TRNF PLEKHM1 POU6F2 MYPN NBEAL2 SRD5A3 LRRC6 MIR17HG FGA KCNE1 B2M COG4 NHP2 CCDC22 TBC1D24 IGF2 KCNA5 CORIN TNXB MYT1L RAG2 MYL4 NDUFS8 DCAF17 PRKG1 NLRP3 FGA FOXRED1 MPLKIP TLL1 HESX1 NSMCE3 CCDC22 HADHB RPL35A EXT2 SCN1B NDUFB10 VPS35 NDUFS4 C8ORF37 ACTA1 HBB GABRD TGFBR2 APC BRCA1 AIP SNX14 SGO1 NDNF SCN5A NOTCH1 SDHD NCF2 FOXRED1 KIF5A HRAS TRNS2 ADNP PEX16 SDHD IL2RG MEFV TULP1 ATM ODAD3 RYR1 NDUFB11 CYBC1 SMPD1 CDON FIG4 DMD TREX1 ELP1 C2CD3 TWNK PNP BACH2 CRX TXNL4A CCDC115 KISS1R FUT8 ROM1 SUGCT PPA2 FAS CCNQ ERCC2 COG6 CBL PIGL GPC4 COG8 DSP NOD2 ODAD2 RAI1 CBL TGFBR2 CC2D2A MALT1 COL4A3 KDM1A SIK1 TAB2 TMEM237 SEMA4A PPARG SLC12A1 SLC37A4 VPS13A MYH7 TERT FAS TNFRSF11A COL1A2 ATOH7 DSG2 DZIP1L BCORL1 COPA AKT1 FRAS1 NSD1 LTBP4 YARS2 NPM1 DLEC1 ND6 TACR3 TMEM237 PML ND2 POLG IL12B MYMK NDE1 DISP1 ND5 TTC8 RPS10 KDM3B NODAL KIT PLG INTU CD46 HSPG2 AIPL1 RGR RSPH9 TERC CD19 CEP55 NOS3 RDH5 KCNH1 VHL GPR101 PMS2 HSD11B2 MCCC2 ANAPC1 B9D1 PGM1 TTN SLC26A3 IFT140 RNU4ATAC LMAN1 CRYAB GNS GNAO1 ABCC8 PLEC SDHB SMARCA4 RPS19 GPR101 RSPH4A AEBP1 RNASEH2C OBSL1 PEX1 LAMA4 PRPH2 FANCB ND2 POMT1 LIPA SPTB TERC CTNNB1 NR3C2 PDGFRA NTRK1 KCTD1 ANGPTL6 ASS1 ENPP1 SH3PXD2B IL2RG KRT14 RET PTGIS MED13L TRIP11 PAH PRKAR1A CNBP KCNQ1 COL2A1 CHN1 ELAC2 COG2 TMEM43 FLT4 RYR2 DBH FBXL4 ATP5F1D UNC13D SOX10 CACNA1S KCNH1 RNU4ATAC FOXH1 CDH23 PIEZO1 SOX4 JAK2 COL1A1 GTF2E2 FOXC2 NF1 PRF1 GPI GFI1B POLG AKAP10 DVL3 IGSF3 PSTPIP1 CRYAB RHO DGCR8 SMCHD1 MLH3 SIN3A SCN5A ERCC2 GATA4 SPINK5 FANCL NDUFA1 NOTCH1 NAGLU DLD STX3 MCCC1 ND2 GNPTG SDHB NEK1 POLH TMEM67 BRAF DSG2 MAN2B1 ARSA CALR HJV BRAF MYLK COL4A5 HADHB PAX3 SEMA3E RASGRP1 KIF7 LYST TKT H19 XIAP APP LRRC56 CITED2 COL4A1 FKBP14 WDPCP MCM4 RAG2 FAM149B1 PEX19 PHGDH PRKAG2 TNFRSF13C RPL26 SBDS POMT2 COL6A1 KIF7 MEFV PTEN TGFBR2 SLC2A10 OSGEP ELOVL4 SVBP VPS13B FTO RNASEH1 ALB COL1A1 GAS1 GATA4 NT5E PLN KRT14 HIC1 ANKRD11 SURF1 SIX6 RRM2B TACO1 TRNK ZFP57 VANGL1 LMNA GNPTAB FANCG TBX6 RAD51C ATN1 ELANE CASK PIGO SHH MYPN F8 KIF20A ARHGAP31 IDH2 MERTK KCNQ1 RAF1 SCNN1A PRKAR1A SIX3 CYP27A1 MUC1 DST MITF SMARCB1 RPL27 NKAP TOR1A RAI1 TRNV RBP4 RB1 DNAAF4 HPSE2 TCIRG1 FAT4 CYP3A5 CALCRL CSF2RB ALDH18A1 BMPR1A SAMD9 LPL CLDN1 NFKB2 MYD88 SELENON POLR1D STAT2 SFTPA1 TPM1 SKIV2L COL18A1 LAT TPM1 SKI KCNJ5 SEC23A LORICRIN XPC MTFMT SGCD GAS1 ATP6 STAC3 TRIP4 KCNJ2 ARX FLNA TBX1 ABCA3 GATA1 PKHD1 ZAP70 HTRA2 PAX3 VIPAS39 DYRK1A BCOR RAB23 FLCN CYP24A1 FGF23 CHRNG ACE NSD1 PIGQ TSR2 IL12A SGCB ALDH18A1 CDKN1A CCN2 ARL3 DKC1 FBN2 CASQ2 BAP1 ALX1 DSE SCN11A ROR2 HAVCR2 NDUFV2 DGUOK RIPK4 COQ2 TAB2 RPL10 PRKCD F2 CLCN2 C1S PEX7 SLC22A5 SH2B3 BUB3 GAS8 NTNG1 GNAS CYP17A1 RPGRIP1 LDLRAP1 TMEM127 ARL3 KRT1 DYNC2H1 TREX1 HOXA1 NR3C1 FGB LCAT KCNE5 PLOD3 COA3 SCNN1G TGFB3 SDHAF2 SDHD SLC39A13 STAT1 RDH12 PHOX2B TMEM237 FBN1 NRXN1 ABL1 CHD7 GP9 CTSA ERCC6 MMP2 CDAN1 CERKL PQBP1 NDUFS7 CYP11A1 LIMS2 XPA PDGFRA OFD1 VHL CDK13 FLNC LRBA TTC8 GDF2 TNNC1 PRG4 LAMC2 MMUT TRAF3IP2 KCNQ1 KATNIP FANCD2 GBA PYGL APP CR2 PIK3R2 IRF5 VPS45 PDGFRB CYP11A1 TRNQ RRM2B DSP CTSB RFC2 BCL11B NCF1 ALG1 CD3D PRCD STEAP3 MEOX1 SLC7A14 WT1 TANGO2 TLL1 TRNS1 SPTB MLYCD CASQ2 CTSA CST3 DDX59 NAGS TMEM260 ETHE1 NLRP3 PEX19 RAD21 TAPT1 MYH6 SLC7A7 INS MED12 CENPF HLA-DRB1 MAP2K1 NDUFAF4 NFIA PPA2 AFF4 POLE SMG9 MGME1 BMP2 RARA EOGT DYSF PTH1R PTH1R CACNA2D1 CBL ACTA2 GJB4 NAXD NDUFS4 NPM1 PTEN SMAD4 MTTP SOX3 TMEM216 CASK CEP290 FGA SP7 NOTCH1 PKD1L1 ACTA2 AIRE PHKG2 NDUFB8 WFS1 IFIH1 KRAS PEX1 PEX12 FBP1 CYLD VCL ZNF423 BRCC3 SLC35A1 ARSB MMP1 COLQ AGBL5 RPL27 WDR1 RHAG APOE SCNN1B AVPR2 OTULIN PIK3CA LMNA MID1 GPC3 PALLD GAS1 SOS1 AQP5 GALC MYH9 ABCC6 CRTAP RERE MKS1 PRKCSH CACNA1C KBTBD13 MKS1 ACVRL1 MPL FAT4 DOLK RIPK1 TGM5 FOXE3 DEAF1 NDUFAF8 HADHA CALM1 MRPS14 PSAP PEX12 ITGA2B PRDM6 ABCA4 LRP5 TNFRSF13B POMT2 PDE4D GRIP1 PIGW TGIF1 CLCN7 LAMP2 SMC3 MECP2 TCTN3 ATAD3A JAG1 PET100 MAPT RANGRF IL12A KRT18 TDGF1 GUCY1A1 CERKL TRNW STRADA PROS1 CDSN TGIF1 PRKAR1A ZNF687 NOTCH3 EHMT1 NOS1AP TGDS POR ANO10 TCIRG1 SDHB SPAG1 ATP6AP1 LFNG INSR CEP290 LRP1 IDUA WDR26 KRAS PHYH SDHB WNT5A SCNN1B CISD2 TRIM28 CFAP53 KRT5 POLR3A RSPH1 AKR1D1 FGFR1 TFR2 LIG4 IL7R TPM3 RMRP GNB5 DNAAF5 NXN GP1BB DNAH1 ENG KDM6A IQCB1 MINPP1 TBX20 HES7 LMOD1 TRNT GLIS3 FOXH1 TRNL1 DNAH9 DNAJC13 ALX4 ANTXR2 PRPF4 PLD1 GSN SMCHD1 RP2 ENPP1 SMARCB1 VHL TOPORS MLXIPL NKX2-5 HLA-DRB1 ADK MYH7 DNAH5 CPS1 TF CACNB2 EYA4 ND1 CPLX1 ITGB3 RYR1 CHST3 CYBB DPF2 BBS2 TP63 ERCC8 KRAS CDK10 SUFU MSX2 PEX13 GAS1 RPGRIP1L SFTPB DSP FBN1 ASCL1 GATA5 FBLN5 ISG15 GJA5 UFD1 TNFSF11 SCNN1B SERPINA6 NKX2-5 FHL1 TSC1 TXNRD2 APC PIK3CA YY1AP1 MMP2 CCDC65 GNB5 GATA6 ARID1A CACNA1S WAS SCNN1G NDUFA11 RAD21 KRT1 RAB27A MSH2 HLA-DRB1 CYP7B1 MAFB CDON PDCD10 ALX3 TBX1 TMEM67 INPP5E MYORG CCBE1 ITK LRP2 NPHP1 SCNN1A NPHP3 SCN4B PIK3C2A TMTC3 REEP6 GATA6 ELN TTC37 BTK RS1 RLIM IL7R ISCU HLA-DRB1 ACTB POMT1 LHX4 PSMB8 SAG CALM2 FANCE FCGR2A ADAMTS10 AKT3 CFHR3 RAD21 GPC4 COL11A1 UROS RAC2 CD19 NAGA CP ARL6 AIP CPT1A INVS NFIX FANCI FBN1 BAG3 DISP1 PRDM16 DNAAF5 FLRT3 NF1 FGD1 AIRE TNNC1 WNK1 PIK3CA SMARCE1 WRN BCR KCNQ1 SRCAP GP1BA TRNS2 SDHB GJA1 PCNT MRAS SGCB CASR DPM1 IDUA TOP3A ZAP70 MEN1 CYTB MYH7 NOD2 GNE ZEB2 ATP5F1E NODAL F13B LETM1 USP9X KRAS MAFB RORC PSMB9 PLAU FLT4 WNT4 TBCK ZNF469 FMR1 COX6B1 UBAC2 NKX2-5 LBR NME8 TRAC HEXA CRB2 PEX1 SLC26A2 HABP2 RERE ALMS1 AQP2 SERPING1 FOXP1 EYS RUNX1 TRNK FLT4 ASAH1 SNTA1 ACTC1 ARID1B HELLPAR KRAS DGCR2 MIF PROKR2 ABCA1 CCBE1 TSPYL1 MOG BBS5 TRPM4 STX11 IRAK1 CPLANE1 AAAS EVC PEX6 DDR2 ECE1 TMC6 FGFR2 PPP2CA RET MKKS B3GAT3 RAG2 C1R HYMAI PIBF1 TERT HMGCL ANTXR1 NDUFA11 IRX5 BTK HSD17B10 CAV3 GNAI2 RPS6KA3 CYP11B2 FTL CITED2 NDUFA12 SDHD TTN CSPP1 KCNJ2 KNSTRN TMEM216 CDON BRAF FLAD1 FZD4 ICOS TMEM126A KCNN4 FHL1 NNT PPP1CB DHDDS BMPR2 NDUFB11 ATAD3A STN1 DSC2 MYH7 NOTCH3 ERCC4 GPC4 IL36RN CNGA1 PEX16 PTPN22 NDUFA2 GATA4 GREM1 HPGD COX7B PSEN2 COL1A1 THOC2 DCLRE1C CHCHD2 GLB1 BTNL2 FLNC CCND1 TNNT2 DNAJC21 CAV1 PCCA TSC1 TRNK MEN1 DMD TNFRSF13C EPHB2 ADAMTS2 HMBS ADA2 SLC4A1 CFTR CAVIN1 C4A GANAB GBA NKX2-5 WT1 FKBP14 CLCNKB PPP1R15B SOX18 CCR6 IFNGR1 BSCL2 TCIRG1 DDX11 STAT4 PDE8B CHST3 AMER1 TMEM216 TJP2 NDUFS1 PDGFB ARVCF PROC NFKB1 MTFMT PGAP2 SLC26A2 DNM2 RECQL4 MKS1 KCNJ11 EHMT1 POLG XRCC2 KLHL7 FH RECQL4 NCF2 RPS6KA3 GGCX NDUFS8 CD28 MYH9 NT5E SLC25A20 SDHD NDUFS2 KRIT1 COL3A1 WHCR ND4L CD2AP MAP3K7 JPH2 GATA2 TRNQ LIAS RET ESCO2 SFTPB EXT1 SPEG CYP11B1 TET2 BEST1 MBTPS2 COL2A1 NF1 OFD1 ANOS1 PHGDH HRAS TKFC TALDO1 TRIM28 TCTN2 GATA4 CD79B KDM6A TRIM8 FBN1 SLC25A13 FDFT1 POLD1 MAP2K2 NFE2L2 PIK3R2 MCFD2 CAV1 DOLK COX3 SMPD1 NLRC4 ECHS1 PIK3C2A COX8A GBA DNAJC19 PIK3CD NDUFB11 ENG ATP6 ALOXE3 ND6 DPM3 PDE6D ITGB3 SRP54 SCYL1 SOX11 EBP ERCC6 F11 IL17RD SLC30A10 EPHB4 COX2 CHRM3 MVK SDHC GREB1L DNAL1 CRB1 SH2D1A PEX3 CHRNA7 GLRX5 MAP2K2 GNE ACAD9 CD27 FN1 BSCL2 LTBP2 HNRNPU NEUROD2 GATA5 SOX9 ELN KLHL7 GDF1 MAX TDP2 LTBP3 CASQ2 ADAT3 TBX20 STAG1 STAT4 ADA2 FBN1 SMAD3 FGFR2 TCOF1 GMPPB NDUFS2 FBLN5 KDM6A RYR2 MAD2L2 SPRY4 TACO1 CLN3 MPLKIP RPGRIP1L SCNN1A RPGR RFWD3 HGSNAT CCND1 PROS1 ERCC8 UPF3B CD81 CARD9 LRRC6 PORCN MED12 DNAI1 IDH3A PKP2 SCN1B CTBP1 TNFRSF1A BRCA2 TBX1 CHRNA3 MPL STX16 ERCC1 RAG1 TREX1 SMPD1 ALG8 TBXA2R CHD7 ELN HADHA A2ML1 ENG STAMBP SDHC NEK8 PDE3A CFI ELP1 SALL4 APOA5 ESPN TBL2 EMG1 WT1 SRCAP JUP DMPK PEX5 DLD PPARG DYNC2I1 CASP10 IDS LTBP2 KDM5B IRF8 GBA TRNS1 DISP1 TRNE IVD ELN SNX10 RNASEH2A LAMA4 TRIO NDUFA10 SLC25A22 ARX LDB3 GNPTAB ERCC6 CACNA1C ALOXE3 KCNH2 SRY PIGO P2RY12 FGFR3 ABCC6 LEMD3 CLEC7A WDR37 DNAAF2 NOTCH2 CAV3 FOXRED1 ZIC3 EXT1 TNFSF15 PIGA MAP3K20 FBN1 KCTD1 DMRT3 CFAP300 PIEZO2 SLC25A24 CTNNB1 SCN10A TNNT2 GPC1 RYR2 SOX2 PSEN1 DNAAF6 FOXC2 INPPL1 ITGA8 EMD NID1 SERPIND1 IFT172 GJB6 PTF1A HBA1 MYC COL11A2 PDE6A PRKCD HYLS1 TNNI3 LYST BTD KCNQ1 EZH2 MED25 SDHC CTLA4 ADD1 RYR1 MNX1 AGL NDUFAF4 RLBP1 CD244 NAGA TUBB GATA4 PTPN11 AIP SLC25A4 FKRP FHL1 EPG5 NRAS PRKAR1A HIBCH TREX1 BCOR KCNJ1 FBP1 NEB SLC35A1 DNMT3A PDGFB MRAP PTPN14 RFWD3 CDH23 RPL15 FGFR1 RNF113A NODAL BICC1 GATA1 TTC8 GBA CST3 STRA6 RAC1 WRAP53 NR0B1 PIGM TMEM70 UQCRFS1 NDUFV1 CTSH PYGM ARID2 SEC23A IRF8 VHL BLM ACTA1 CD40LG ICOS CAV3 RPS27 CFHR3 PTEN ABCC9 COX14 THPO TDGF1 GGCX MED13L KIF7 NPHP1 NDUFA13 SELENOI PIEZO1 CYTB RP1 DDX6 BRAF WDPCP HBB ZIC3 MRPL44 NOP10 WNT10A FLNA ERCC2 CALR FHL1 ACD NEB HABP2 DPP6 PHF21A MYBPC3 NIPBL ITGA2 HYOU1 EGFR ACADS DES TPM3 RPL10 MTRR PGM3 KCNQ1 MTTP IL7R STAG2 STXBP1 PSMD12 FLI1 CITED2 TMEM43 SMAD4 PRKACG IFT81 HLA-B SPINK5 KCNQ1 RNASEH2C SP110 RBM8A TIMMDC1 ATIC BAG3 SLC39A13 IGH TOP3A DPP9 TMEM231 DCLRE1C SDHD GJA5 TGFBR1 TNFRSF1B WARS2 TNNI3 GTPBP3 ITGA2B TXNL4A AP3B1 TCTN3 GPC3 DVL1 FLNB KCNQ1 TTN NDUFAF3 AGA BBS10 FOXP3 KYNU COG5 FN1 PCSK9 TRMU SOX10 DNAH1 KCNJ18 OSTM1 HADHA AKT1 FKTN BBS2 ACADVL RPL26 DISP1 RNF213 CDKN1C SH2B3 GLI2 GLI2 COL4A2 EDN1 CYP1B1 TSC1 JUP TRRAP GATAD1 CHST14 IL23R BOLA3 MGP PLIN1 CFAP300 STIM1 SCN5A UMPS CTC1 ZMIZ1 SFTPC XPC CHD4 ND6 FRG1 ANK1 FKTN STK11 SPEG AK2 MASP1 GNAQ MYCN MYH11 LRP5 SOX3 PHYH HFE CDC42 TASP1 FOXA2 DGCR6 TEK HOXD13 B3GALT6 RPL5 SLC39A4 KAT6B NEK2 ACTA1 PRKAG2 SMN1 NLRP12 GDNF CHKB ABCG8 PEX10 MVK COG1 TP63 IFT27 SPEF2 COL2A1 ABCA4 ND4 CFI LRAT ATP5MD RAD51C MLX SEC23B FUCA1 PKDCC FGB HPS4 PIGT JAK2 ALG1 AHCY FOXC1 SUZ12 PIK3CA VCL DOCK8 DNAH9 LOXL1 COX20 HCN4 KLHL41 RAI1 RMND1 PIK3CA HRAS AFF4 ERCC2 DHX38 PTPN11 KCNE2 IFT172 ND1 RIPPLY2 NDUFAF6 MYBPC3 GGCX FAM111A SPP1 NSDHL ZFPM2 NDUFAF2 TBX20 VCL SPECC1L CPT2 GYS1 CLCN7 PTCH1 LEP LBR IGLL1 NOTCH3 PPCS SCO2 PTCH1 OTUD6B PIK3CA NKX2-6 PORCN FLNA TK2 FLNC SLCO2A1 FAH XIAP HES7 GNAS MEGF8 CD3E ABCB6 KCNJ8 EPCAM ATP6V1A TDGF1 VWF PEX6 MAT2A NFIX PSMD12 SCN3B ZNF462 RNF168 TBX5 FYB1 CYB561 ATM NAA10 COL5A1 ATRX MPL SERPING1 ATP8 ACAD9 PTEN SLC12A3 SLC25A3 PKP1 CPT1A TGIF1 ADA PSMD12 UBR1 PIGN BCOR NEK9 IKZF1 AGT TSC2 LEPR WIPI2 RASA2 CARS1 EPB42 LTBP4 BTK STIM1 INF2 APOA1 RPS20 RUNX1 KCNA1 TNNT2 WT1 NDUFS2 COMT CDC73 SBDS SCNN1G ARL2BP POLH GLA CTSB CLCN7 BBS1 PIGV LAMB3 MTHFR TPM2 ANK1 STXBP2 CSRP3 ACTB PTCH1 CPOX C12ORF57 IL1RN TP53 CCDC28B SNX10 TGFB1 GP1BB ALPK3 SALL1 VPS13B NDUFAF5 STN1 HAMP XRCC4 PIGT NLRP1 ABCC9 SOX18 ELMO2 ACP5 TWIST1 FLNA TRIM37 RPL31 FLNB SRD5A3 EPB41 SLC4A1 DMD WNT4 SERPINC1 CCN2 HNRNPA2B1 RET SMAD3 RP1L1 SDHB TREX1 CNGA1 HSPG2 AARS2 ATP7A MSH6 F5 TALDO1 RPE65 C2CD3 GLI3 FGFR1 SIN3A EYS SRP54 TINF2 BUB1 ARL6 KCNE1 AHI1 SMAD4 SHPK ATP7B ERCC3 TXNRD2 SCN5A SELENON GATA6 WAS ACSL4 MAPK1 F7 KCNJ11 DOCK6 YY1AP1 PDE6C PIK3CA MEFV DLL1 FLI1 CCR1 TRDN COQ2 COX4I2 FSCN2 HIRA JAM2 KRT2 TBX1 GATC NHLRC2 ACADVL COQ4 PPARG CTLA4 GJA5 MKS1 LEMD3 HLA-DRB1 PYCR1 ADAMTS10 IGF1R CHST3 KRT10 SNRNP200 CACNB2 TBX3 PSAP RAF1 COL5A1 NABP1 FBN1 PRKAR1A NUMA1 FECH MYO18B DLL4 COL7A1 DDB2 TBX1 BMP2 FCGR2B SIX3 CALM3 SDHC LIG4 COA5 LAMA3 GMPPB MTOR NOTCH2 KAT6A BBS12 GNAQ NUP155 TP53 SCN1B SERPING1 SYT1 NPHP1 BMPR1A EGFR ABCC8 LYST LRP5 RNF125 GATA6 SCNN1A FGF8 PKD1 BBS7 BIRC3 ELN KMT2D DIS3L2 SMARCAL1 NR2F2 EPHB4 KLF1 IL6 TRNL1 KIF1B GNA11 KCNE2 ARMC5 FADD CCR6 KLHL3 HRAS HYLS1 LMX1B ADA RAG1 ACTN2 BRCA2 RPS17 SIX3 SDHA ABCB11 TNFRSF11B VWF APOE PCARE KYNU SOX4 SETD5 WDR19 TWNK POR TNFSF11 MGAT2 HK1 DNAAF6 IGHM DLX5 THOC6 TFAP2B OTX2 PEX2 SERPINF2 ZNF469 B4GALT7 CACNA1D BBS9 FGG PEX2 SETBP1 HOXA11 LMNA CTNNA3 WT1 KRT14 HYDIN CD40 CD28 SHH MNX1 SEMA4A MECP2 KCNK3 DSE ND6 DDX6 KIT FLNA B3GLCT KRAS ITCH SPAG1 TRDN GJB2 LMNB1 TSPYL1 IDUA DLL1 NDUFS4 ZNF513 FGFR3 KCNQ1 SLC19A2 PPP1CB MYOT RBBP8 TRNS1 CDON PRKACA RAG2 RPL11 KCND3 MAP2K1 MC4R STAR SCYL1 GYPC TBX4 SPATA7 NODAL GABRA3 RARB EDA2R HBB COX3 FGB MBTPS2 TMEM126B SUFU MYOCD NAA10 TSC1 PCCB FAS G6PC3 MS4A1 PROC LMNA KRT5 ZDHHC9 TRAIP RRAS2 MYH7 MED12 NEU1 CYP11B1 ZNF365 RAG1 NDUFA10 IGF2 PROP1 AUTS2 FANCD2 BCL2 TBL1XR1 PEX12 ACTC1 TWNK GATA5 LMNA DCDC2 MRE11 LMNA SEMA3A ABCA1 CNTNAP2 TMEM67 SLC2A1 BCL6 TRMT1 PSEN2 DLL1 LMX1B FOXC1 CNGB1 EMD GAS1 NDUFS3 TRAF7 HCN4 FKTN ANK1 PIGY HESX1 ACTN2 PGAP3 SMOC1 RPS29 TGIF1 PEPD TERT BAG3 ERCC8 FIG4 CDK4 TAF2 NUBPL SAMHD1 RBM20 ACTC1 MAPRE2 MAP3K7 SDHA KPTN KCNH2 ADA PIGY ATP7A IGFBP7 NUP107 C3 PKD1 CCDC141 FBLN5 NFKBIL1 PEX14 DSG2 TNFSF12 RASGRP1 GLI3 SDHA DNAL1 MLH1 MC2R AGPAT2 KCNN3 GMPPA KIT B2M FOS DYRK1A PEX7 KCNJ5 PAM16 EXOC6B ABCC9 SMO TBX1 CDKN1B CHRNG CYP7A1 ACTG2 CALM1 AMMECR1 DPM3 TMEM138 TNNI3 ADNP CYLD PAX6 KCNN3 NDUFV1 SCO2 CFAP221 RGR PKLR TSC2 MSX1 KDSR CD96 SCN2B SCN5A MFAP5 CLIP2 BEST1 PIGT PIGS SCN1B PDSS1 TGDS POR POMT2 CEP120 HNRNPA1 PPOX ATR GAS2L2 FASLG ALOX12B TPM3 IL6 AIP LDLR XRCC2 MTM1 CDKN2C PSEN1 MYH6 STAT3 IFT172 ANKRD1 SFTPA2 ITGA2B ATXN7 PDGFB B9D1 CDON ASXL1 CDKN2B COL3A1 TTPA PDHA1 MAGEL2 INSR PARN MAP1B NRAS NPC2 TP63 PRKG1 MYH7 PKD2 BLNK DIS3L2 DES CSF2RA SMOC1 MYPN ZIC2 SH2B3 HACD1 TBC1D24 AHCY CEP290 PCNA SUFU GPX4 PRPF3 NONO IFT80 EXT2 MYMK PARN FGFR3 SCN5A XPNPEP3 COQ9 TP53 NAGA NAGA TAZ CACNA1H SLC22A4 KCNAB2 USF3 GCK H19 HDAC4 ND5 PTCH1 SCN5A CR2 MYPN TNPO3 F5 F5 MPL HADH SERPINF2 DSP SHH HSD3B7 NDUFB11 AK2 ND4 ASXL1 GLI2 MYOC AHR TNFRSF11A SRSF2 SDHB NUP107 GATA6 TET2 SCN2B CCDC8 CTC1 KITLG NDUFV2 TBX1 IMPDH1 IGBP1 ENPP1 CFAP410 SOX6 PACS2 GPX4 BMPR1A SKI ASXL2 TERC ADAMTS3 TOPORS COG7 PUF60 CAP2 AGPAT2 MRPL12 TTN DVL3 IFT43 DSG1 SOX10 SNIP1 SCNN1G TBX2 GNB3 NGLY1 TF CYBA PIEZO1 SEC63 TMEM126B INTS1 CDIN1 FRG1 GBE1 TRNW RTEL1 PEX5 TET3 PCNA KRT8 MYPN ITCH PNPLA2 FOXP1 GNB5 MYO5B DNAAF1 PEX7 FGFRL1 AMMECR1 SUMF1 MTMR14 TPM1 FGFR2 CREBBP PDE6G NDUFAF2 CEP19 APC NDP HLA-DRB1 TERT PTPRC MC1R SCN10A GDAP1 SMO NAA10 ERCC6 SFTPB CACNA1S EPHB4 KAT6B NDUFB9 RFT1 CFAP298 ACTA2 KIF1B CPT2 IQSEC2 NSMCE2 COA8 DNAJC19 MYLK2 MESP2 ERF WDPCP ZEB2 SIM1 TANC2 LIPC TAZ FBXW11 TPK1

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0001626: Abnormality of the cardiovascular system
    Genes 4365
    NR2E3 ND4 MMUT EDNRB NDUFS6 TMEM94 LPIN2 COG4 VEGFC PGM3 GATA1 PDE11A KIAA1549 SLMAP LBR CD247 RHBDF2 AGK ABCD3 SEMA5A GP1BB HS6ST1 FANCC SEC61A1 SEC24C PROM1 CALM1 TRNL1 ANK2 NELFA HPS3 STING1 GDF1 MMP14 APOE PEX11B POLR1A OFD1 ABCA12 FGF20 ABCG8 CCDC141 NSD2 CYTB HGD KRAS NKX2-5 JUP KCNH2 TRIP13 FEZF1 PERP IKBKG BTD LDB3 GDF1 RAD51 ERCC4 FGB NDP SLC25A4 ASXL1 CTLA4 ABCC9 LBR FLT4 KCNJ2 SEC31A ATP6 USH2A FLNC GATA4 MYH6 PLEC NSD1 FHL1 GLB1 TSC2 LMNA CAVIN1 TNFRSF4 FLT4 GUSB AIP EVC C12ORF57 RET RNU4ATAC PPP2R1A TPM3 XYLT2 COQ2 FBLN5 HBA1 LZTFL1 ACP5 NUP188 IL7 MAP2K1 ROBO4 MYLK PUF60 FKRP TPM2 TTR TSFM TMEM67 FGFR2 SPOP IGH KDSR DNAJC21 LETM1 ACTN2 POMGNT1 PTDSS1 MYF6 CD70 SOS1 ATP6V1A GJB6 NPPA ACADM GATB TERF2IP GLI3 G6PD HNF4A MGMT COA6 RERE KLLN IFNG ARNT2 FANCM WT1 PDE11A FOXP3 USP45 MYCN UBR1 MYOT IARS1 ENG PLEKHM1 GJA1 GLI2 DNAJB13 PRKAG2 FLT1 INVS IDUA CCDC174 NOTCH3 HPGD HIBCH CAV1 IFNG HLA-DRB1 JAG1 ARL13B GFM2 HOXA13 COL4A1 GBE1 SALL4 CFHR1 TBXAS1 DDX58 TGIF1 MKS1 LACC1 DNAJB11 ND5 RPS19 H19-ICR BLOC1S3 CDON PRPF6 PLCB4 GPD1 SLC18A2 FGFR1 EVC2 NEDD4L BAP1 RPGR THPO MST1 LAMA2 HPS5 ADAMTSL2 PEX14 RAB23 NDUFA6 MYH7 ESR1 EDA VCP KCNE3 ZIC2 KMT2E HFE SDHD C2 ITGA2B TET2 CAV3 ALDH3A2 PEPD FGF8 RAF1 SHH XYLT2 PSMB4 SON HMBS TLL1 DTNBP1 ABCD4 FHL2 MMEL1 NODAL JAK2 HEPHL1 TAZ HAAO BUB1B ERAP1 ADAMTSL1 CSTA SMC1A ZNF148 LZTR1 MIB1 CLRN1 FMO3 TMEM231 PRTN3 PIGN CHRND TRNF LRP6 TDGF1 NDUFB11 COL1A1 SCARF2 PTPN22 UBE3B DPF2 ANKS6 DNM2 XK KRAS HEXB IDH2 MYH6 IRF5 HLA-DQB1 ERBB3 DUX4 TBX19 SIX3 IDH3B MTHFR FANCB TERT EPB42 TRNL1 ZEB2 ODAD1 NECTIN1 COX1 ARCN1 COL1A2 LDLRAP1 TP63 SMAD3 F13A1 CAV1 GJA1 VPS33B CASR WDR35 LIG4 LARP7 CCDC40 CUL7 DDRGK1 IL2RG PLOD1 HAND2 PRRX1 SACS SCN5A WT1 CD96 WT1 TGFB3 PRPF3 ACTA2 BBIP1 SLC4A1 HAMP LMNA GBA CYP11B1 SGCG IDUA TRNL1 CTSK KLF1 ABCC6 SIM1 SETD5 SAMD9L SF3B1 ESS2 NCF4 DRC1 FERMT1 TPI1 NFU1 NDUFS2 COX7B SCAPER DNAH5 SAMHD1 MAN2B1 KCNJ18 FXN AGXT ZMPSTE24 ALDH18A1 ACTL6A GFI1B D2HGDH EOGT GP9 CEP290 HCCS SMARCB1 PIGV GMPPB TRIM32 DNAAF4 HPS1 KIF15 ODAD4 SPECC1L TDGF1 PMM2 SGSH WAS SOX9 DCAF8 HAVCR2 ND5 CDKN2A ARX GNPTAB SEMA3E IL17F SCN10A LRRC8A SLC35A2 CCNO LMNA MYL2 SOX2 NKX2-5 NOS3 SETD1A NEXN BMPR2 CDK8 POMT1 ERGIC1 TMEM127 NCKAP1L CC2D2A JAK2 HNF1A BAP1 DKC1 CYBB COL1A1 PAFAH1B1 VHL SCN5A TTC7A FOXH1 NDUFAF5 TNNI3 SLC25A11 PAFAH1B1 ND1 ITGA8 GLMN MYD88 EIF4G1 ARF1 KCNJ5 SLC20A2 PRNP RRAS XPA GATA4 AKAP9 STRA6 SDHA FGF17 FANCC TRNW ARMC5 COA8 PSAP DHCR7 PTCH1 CALM3 MEN1 CLCNKB MAB21L1 PROK2 CKAP2L CC2D2A F7 BPTF COX10 MGME1 TKFC ADAM17 CRYAB PLAGL1 ABL1 NDUFS1 WASHC5 SMARCE1 INTU ERCC5 ACTN4 STAT3 DYNC2LI1 TRNV HGD HYMAI WNK4 LIFR SHH AEBP1 MEFV DNAI2 AKT1 ND4L NFIX NFKB2 DCDC2 PIGL TGFBR2 ATP6V1E1 XYLT1 CRELD1 PTPN11 DLST MYH7 FOXF1 SDHAF1 TGFBR3 GDF2 LARS2 GDNF RPS6KA3 PROKR2 APC2 TNFRSF1B CTNS SMARCC2 FGFR1 PQBP1 COX15 PPOX F10 PNP GLUL PKHD1 NKX2-5 HYLS1 CAV1 BLM ASCC1 MYH6 MEIS2 KCNJ11 TFRC IDH1 PEX6 RPS26 COL6A3 CIB1 SOS2 RPL18 DVL1 RHO TGFBR1 RPGRIP1L TRNK CEP120 EPB41 CYP7B1 FECH SF3B4 UBE2A CRYAB MNS1 FGFR2 MEOX1 VAMP7 LMNB1 GP1BA ARL6 JAK2 NDUFAF1 SRY CFC1 DNMT3A EPAS1 KCNQ1OT1 WNT10A TANGO2 GATA6 TNFSF4 DYRK1B GATA6 BSCL2 RUNX1 ATP5F1A AKR1D1 DHCR24 OFD1 ABCC9 USB1 TSHR HTRA1 THSD1 SMC1A SVBP GYG1 ALB F8 COL2A1 TFAP2B COL3A1 ABCG5 ALDOB DLL1 IFNGR1 SDHB TNFRSF11A CEP57 CASP10 PTPN22 RAB3GAP2 ABCA4 TERT POGZ F8 CA2 PIGP PEX11B NOTCH2 COL5A1 NRXN1 CD81 NODAL MYBPC3 ANKRD11 SDCCAG8 F13B PPARG NDUFA2 CSGALNACT1 SF3B4 STXBP1 BCOR HADHA SNCA DNMT3A ARL2BP DSP KIF11 WRN SLC37A4 GNAQ SCN9A AGXT EDNRA AVPR2 CCND1 RYR1 ATP6V0A2 XYLT2 MYL3 NBEAL2 ODAD4 CACNA1C FGF8 RIT1 RLIM GATA1 TFAP2B TMEM43 F9 MEF2A DISP1 CNGA3 GPC3 TCTN3 PRF1 ETV6 SLC29A3 CLCF1 NPHP3 TCF20 IL17RA CANT1 LMNA FREM2 RAG1 FRA16E LMNA LMNA CPLANE1 DLL1 EIF2AK3 AKT1 HSPG2 FAN1 G6PC NFIX MUC5B EWSR1 ZMYND10 ACTG2 SDHC DHODH SGCG PTCH1 CD79A ARL6 COL5A2 FIP1L1 PBX1 LRP5 SMARCA2 SOX9 RPGR SCO1 SPECC1L GINS1 GLRX5 TGFB2 PIK3CD PHOX2B BRAF ALAS2 TCTN1 SLURP1 EBP ECHS1 NF1 ARHGAP31 GATA4 IDH3B CDH2 CSNK2A1 GLI2 PROS1 ALMS1 PEX26 SIX3 FGFR2 ATRX TGFB2 FGF8 PSAP ACAD8 BCHE NPHP1 AP1S1 CHST14 POLG WDFY3 LRIG2 DCX NDP DNASE1 NIPBL POU1F1 CEP41 OPA1 ARMC9 TULP1 SDHA IFIH1 TWIST1 RNF135 GATAD1 ND3 MYRF ND1 BRCA2 APP IFIH1 ND5 FXN FOXE3 APP BRCA1 FIBP NXN PEX3 ATPAF2 CIZ1 EYA4 ALDOA ORAI1 MTAP CD19 COX1 CEP104 LMNA RAI1 GUSB LRP5 GNE NGLY1 TMCO1 SAMD9 SDHA F13A1 POMP GMPPB GUCA1B PKP2 NPHP4 HDAC8 TRAPPC11 ALDH18A1 PUF60 PTCH2 SMAD4 RANBP2 KIAA1549 MPL SCN5A OCLN THBD DOCK3 SUMF1 SNAI2 MYL2 PIK3CA CYTB FAH STAG2 POLR3A KRT83 SEC23B GATA6 FOXC1 MYSM1 SERPINC1 SARS2 GJA1 CDKN2A ABCC8 CPT2 CBS TET2 PRPH2 ZMPSTE24 SDCCAG8 NR3C2 TCF3 RPL11 NKX2-1 NDUFA4 ZMPSTE24 TCAP PACS1 ALG12 KMT2D RPL15 TGFB1 IGF2 CKAP2L CASR CCDC47 GGCX NOTCH1 RRAS2 PDE6H ADCY5 MYOZ2 HLA-DPA1 CHD7 RPGRIP1 RSPH3 GNAQ SELENON RYR1 CLPB PIGN ND3 SMC1A TGFBR1 IDH1 PADI4 CFH HSD3B2 TRNN SUFU MRPL3 FOXF1 KLRC4 COG7 B3GALT6 SMAD6 WWOX USP9X ATP2C1 PDCD10 PIGU KRT5 KCNJ2 NDUFAF6 CITED2 NLRP3 ESCO2 RPL5 ZFPM2 ELN JAK1 ZFPM2 NR2F2 FGF8 TKT WASHC5 HLA-B CTU2 SETD2 PNPLA2 ATP6V1B2 ARHGEF18 FBN1 JAG1 MEN1 BMPR1A KIAA0753 ATP6V0A2 ZNF423 STK4 GCH1 AKT3 PMS1 C8ORF37 CPN1 RHAG POGZ DSP NDUFS2 F12 JAK2 ATRX TTN BRAT1 FUCA1 CFH ADAR KCNE2 JAK2 NLRP3 CCDC103 CEP120 HBA1 AGK SMARCE1 ERCC5 CLCC1 GPD1L GUCY1A1 PRCD AGGF1 DOLK DCHS1 TRDN CALM1 FSCN2 FAM161A TNNI3K MRPS22 KRIT1 FGFR1 DMXL2 DNAH11 IL17RC FLNA FCGR2C NSMF NAA10 GNAS KDSR KIZ MKKS LDB3 DNAI1 AGTR1 ERCC2 BRF1 IGH LRRK2 GLI2 FGG SNRPB IL10 FZD2 QRSL1 SLC4A1 STEAP3 SLC26A2 OFD1 GJB3 PEX13 SCN9A MCTP2 ANK2 FGF8 PIK3R1 EP300 SCNN1B CASP8 KCNE5 EFTUD2 RP1L1 SCN1B PLVAP FOXH1 IMPG2 SDHAF1 DNAAF1 CDH23 TDGF1 IL2RA MAP3K7 COL4A4 FGA PDE3A USP8 REN AMER1 CC2D2A TERT GJB3 ZIC2 ARID1A WDR35 PRKAR1A PRDM16 RIT1 BGN WIPF1 GNA11 SF3B4 F2 NF2 SLC29A3 SLC19A3 FAS RNASEH2A DYNC2I1 TGIF1 FLNA DCLRE1C SMAD4 BBS1 PALB2 GTF2IRD1 CFI TET2 KDR FADD APOA1 COX7B AKT2 TAB2 PDX1 SLC39A4 MYLK SMC3 FKRP SLC29A3 PLIN1 FLNA FOXE1 SPARC GBA GATA3 COL6A2 PCARE KLF13 BANF1 ESCO2 MYH11 SCN4A FBN2 DCAF17 RTEL1 RPGRIP1L LIPC SBDS KRT9 HMCN1 CACNA1D FANCE KRAS TLR4 ETHE1 GPD1L PEX19 XPR1 TRNC FANCA ODAD2 NEK9 FBN1 IFNG SDHD ANTXR1 ELANE CXCR4 COL4A3 CENPE BBS4 DMD C4A IFT88 UROS KANSL1 MMP1 FMR1 KRT16 F13A1 PCCB TSC2 NR3C1 PRPF8 SETBP1 USB1 LAMP2 TET2 BPGM MVK NKX2-1 SLC17A5 CTCF PNKP DDX3X RRM2B GFI1 RNF113A CLIC2 MAF DDC ALG9 KAT8 TMEM237 NEBL STK11 IL10 SLC7A7 MED12 CDKN2B LONP1 ERBB3 RET JAK3 PEX10 OTX2 SYNE2 AICDA GLB1 GTF2H5 ZFPM2 PLOD1 RPS28 PRDM16 COL3A1 IKBKG ITGA3 ITPA CIITA GBA DOCK6 ACTC1 JAK2 KIT CDC45 CARD11 GALE CFAP298 PEX5 DCC COL7A1 TRPM4 WNT5A SHANK3 MTHFR TRAF7 MAP2K2 LIMK1 NRAS HLA-DRB1 EXT2 LMNA FBN1 SOS2 HBB PSAT1 FANCI MITF TNNI3 SALL1 PAX8 TARS1 NSD2 DNAAF3 DAXX DYNC2LI1 NLRP3 NPHP3 NPC1 HJV TNFRSF1A HLA-DPB1 SYNE2 DSG4 RINT1 LZTR1 SLC25A11 COL1A2 TRAF3IP1 TRPM4 MPIG6B VHL POMK GANAB TCAP NLRC4 EIF2AK4 RPSA GPR35 POMT2 CLRN1 LRP2 STAT5B FBXW11 NLRP3 CHRNA7 KRAS FCGR2A KIAA1109 CNGB3 SELENOI MYOC ATP8B1 CYBA ERCC6 SF3B1 PLN GNA14 FOXH1 MDM2 CAT TCF4 THOC6 PET100 ACTG1 ITGB3 NOTCH2NLC IL12RB1 CYP11B2 ATP6V0A2 CACNA1D PITX2 PKLR TCOF1 GAS1 ERCC4 PLN STAG2 TRNH KIF1B PTPN22 SPTA1 POMGNT1 HGSNAT F10 SLC2A1 ERCC3 IDUA HLA-B COL5A2 GM2A NDUFV2 TWIST1 MIPEP EFEMP2 NCF1 ADA2 RPS15A HESX1 KMT2A F2 IL2RB ERCC4 DISP1 CSRP3 ATP6AP2 BCR RBM10 PEX1 FGFR2 WNT3 COL1A1 AP1B1 GATA1 NR5A1 ACTA1 HCRT PDGFRB FASLG SMAD4 DMPK CYSLTR2 ROM1 CCDC103 CACNA2D1 HBA2 PEX5 ATAD3A FGF8 CCDC39 NEU1 COQ2 POU3F4 LMNA RPS15A NKX2-5 HBA2 PSAP HSD11B2 GJB4 ITGB3 MDH2 CA4 RP9 BBS2 PITX2 KCNE3 PALB2 RAF1 KCNN4 LMBR1 CFB WDR11 PEX2 WAC ARL6IP6 GNAS PLEC FLNA TCIRG1 TP63 NF1 SON PIK3CA NKX2-5 LMNA CHD7 CUL3 NMNAT1 KCND3 SLC4A1 BCS1L CAPN5 CD55 TTC37 LONP1 SHOC2 GJA8 HTRA1 GPC6 ABCA3 STK36 LMNA OFD1 PALB2 TECRL HLA-A SURF1 FGFR2 FMR1 APOB TFAP2A AP3D1 ACTA2 DHPS PEX6 AGT ZMYND10 SOX18 TGM5 TPM2 REST ZIC2 SNRNP200 SC5D PTEN TBX22 CTCF PRRX1 RAC2 CTLA4 PLP1 MEGF8 FGFR2 ZIC2 TAF2 EFL1 TTC8 DDB2 B9D2 PEX16 EFEMP2 PTEN PCNT NEUROG3 CFHR1 PDSS2 PIK3R2 FGFR2 SPIB TGFB3 FANCB USH2A TNXB MYH7 PRPH2 SCNN1G UMPS ACVR2B TRAPPC4 XPNPEP2 PTCH1 LEMD3 CRLF1 TNFRSF13B MYH8 COL1A2 MYPN MCIDAS F2 GNAT2 YWHAE CYP11B2 IVNS1ABP NSUN2 CHRM3 COL1A2 SLC25A4 STIM1 DHCR7 KRAS TMC8 RBM10 DPH1 LYZ KDM6B FAM13A MFAP5 CWC27 TBX3 MRAS MAN2B1 KRAS KRAS SH2B1 ANO5 TUB CDH2 CYP27A1 CBS NODAL IFT122 ACAT1 RBM20 NDUFB3 ROR2 COL4A1 MUC5B USP8 LIPN RTTN CRPPA SMAD4 HBG1 MED25 CCND2 SELENON COG4 RREB1 JUP PROP1 CEP57 DLL4 SH3PXD2B DES CEP41 TBX1 CEP164 RNASEH1 ADCY5 ERMARD NRAS GJA1 GPIHBP1 ZNF408 COLGALT1 PTEN AMMECR1 SDHC ATM DPH1 SLC25A4 AKT1 CYP21A2 FLNA NR2F2 TBX5 GCDH ATP2C1 STAG2 MED13 GATA6 GALNS ACTC1 IDH2 UNG MRPS16 CTLA4 KAT6B SMAD4 CLCN7 POLA1 SCN2A HBG2 RPS7 TNNI3 MMP21 GLB1 SCN4B NDUFS3 PIGL AKAP9 WDPCP ADA2 COL4A1 KAT6B VANGL2 SCN3B ACTL6B EED GLI3 PLCG2 ADAMTSL4 FGFR1 BRIP1 ZNF513 KCNE1 ERCC3 PTPN11 TRPV3 PRKCD FBN1 RIN2 CD79B ALOX5AP TECRL ABHD5 CD46 RAI1 MYT1L GP6 COL3A1 MAP3K7 ARID2 HDAC8 SPATA5 KAT6A BCOR DGUOK CACNA1C DVL3 BCL10 ABCB4 TP63 HLCS TRPS1 NEU1 ACADL BMPR1A RSPO2 NADSYN1 POLG2 GDF6 MAX SOX2 TRIP11 ARID1B SLFN14 POLG2 GAA UBE3A FKTN SNTA1 FGG CSPP1 TERT GDF6 ARFGEF2 DES UBE2T GALNT3 CSRP3 KYNU HCCS KCNMB1 HMGA2 LMNA CPT2 TMPO TTC7A SLC25A24 SKI STAT3 NRAS TTC12 RPS24 INPP5E BPTF FLNA TFAP2A RPL35 SLC2A10 RPS17 SDHA CYP17A1 INPP5E NLRP3 CCDC40 ASAH1 POLR1A CTNND2 MYH3 MVK NOS3 BRAF ATRX KCNJ5 APRT PRPF31 PIEZO2 MED13L KCNQ1OT1 NDUFS8 DTNA CCM2 PHKA2 NKX2-5 GJA5 POU2AF1 SNAP29 PAFAH1B1 FOXH1 SLC40A1 SULT2B1 HADH MBTPS2 FLII FN1 NRL PDE6G RBP3 PHKG2 ARPC1B CDKL5 SMARCA4 SP110 HCN4 TCTN2 ITPR1 FANCA PMM2 RASA1 ROR2 COX3 CEP290 ALPL POLG STAT3 DNMT3B PEX26 MGP ABCC9 OTX2 DLL1 KCNE1 SHH COQ2 ABCA1 EP300 DDRGK1 CLIC2 ITGA7 SCN9A IRF2BP2 CCNQ TNNC1 RIN2 ADGRE2 ALKBH8 NF1 CPOX OTC DHCR24 ARID1B MAK RMRP LIPT1 NEK10 SGCA FGFR2 MICOS13 SOX5 NEXN SYNE1 BIN1 TGM1 PSTPIP1 COL7A1 FOXE3 EDN3 IGF2 H19-ICR B3GLCT TUBB MYCN TNFSF12 PIK3R1 RASA1 F5 SARDH GSN SH2B3 DSP KIAA0319L SLC52A2 CDKN1B LIPA TELO2 SSR4 GJC2 DACT1 TRPM4 GYG1 FIBP RBM8A ZIC2 CDC42 LRRC56 LMNA TNNT2 DNAI2 NONO FAT4 PPCS ERCC8 USP18 VWF SALL4 PQBP1 GBA GJB2 GATA4 PDE6B GATA4 MYH11 HFE EED CDON PROC STRADA TTR SLC26A2 BMP2 WWOX BVES C8ORF37 CALM3 TPM2 CITED2 PTEN DYNC2I2 COX3 SNRPB MTO1 DHX37 SLX4 LOX ACTA1 IRF8 XRCC4 TRIP13 CDC73 ODAD3 DNAAF2 MANBA CFTR SCNN1A PPP2R5D WARS2 CCDC39 PKD2 TNNT2 PRKCH SMAD9 RYR1 ELOVL4 JMJD1C TRNT1 VPS33A ODAD1 ZMIZ1 CREBBP DIS3L2 AGA SETX SGCD BAP1 COX2 SLC25A20 KIAA0586 GTF2I POT1 EFTUD2 ALG9 KIF3B TRDN LMNA ACTG1 ALX4 COX1 ACAD8 ATP6 TRPC6 LMNA LAMB2 ERCC4 GTPBP3 PDE6A HPS6 GATA1 OTUD6B COQ7 LRP5 BEST1 MPI CALR CCM2 HBB VPS33A GDF3 CYP11B2 OTC SEC23B RPE65 ANKRD26 TET2 SCNN1A RLBP1 EPG5 DSP POLR1C SIX3 KRT5 GLA MTHFR HBB RPL35A ND1 FGG SDHD MARS2 CYP26C1 ANTXR1 APOB HLA-B TRMT10C ATP6V1E1 TRNE UVSSA CPOX CDHR1 SLC20A2 RBCK1 TWNK AKAP9 APOC2 NDUFAF3 SAA1 HBA2 KCNQ2 TAF1A NBAS DBH SMAD6 TEK EXT2 ABCC6 FZD4 NKX2-6 RAG1 LIPT1 F8 BAP1 NCAPG2 YY1 LPL TMEM107 DUSP6 SLC25A3 AHI1 PRKACA PNPLA6 RHOH FGFR1 PLAGL1 SNCA CREBBP SCN5A MYH11 EVC2 LDB3 GBA PRDM5 GATA6 WFS1 ND4 NDP SLC25A26 GBA SLC19A2 ND1 NEXN RARB NDUFAF1 ATP7A F5 DCHS1 GJA1 APOE ELN GNAS MAF PLCG2 HLA-DQB1 HBB TCIRG1 RAF1 EXTL3 ATP11A ND6 PCCA TPI1 SOX10 KIT NPPA APP GNAI3 NKX2-5 VAC14 PDGFB BIN1 LIPA TGFBR2 SPTA1 NDUFS7 FOXJ1 NEK1 RPL10 SCNN1B ECE1 KIT ATP7A FSHR CYBC1 SEMA3A SMARCD1 PRKAR1A JAK3 CD109 SPTB PCGF2 LIG4 FERMT1 MYH7 LZTFL1 SGCD IRF5 PTCH1 CA2 SYNE1 NTRK1 CHRNA1 FGA RSPRY1 KCNJ8 FRAS1 ERCC6 RNASEH2B P2RY11 NEU1 GP1BA MYH7 BTNL2 NDUFA9 KIF23 ND2 HSPA9 PIGA MEIS2 CACNA1S DNAH11 GCLC ACVRL1 POMT1 AGTR1 DMD POLG MSL3 PLCB3 GP1BB CAV1 KCNH2 TPP2 FARSB UCP2 IRF6 SALL4 PACS1 GLI2 AHI1 SHOC2 FUZ MAP3K1 MYH6 SRP54 IGHM CRKL C1QBP IL10RA COX15 SLC12A3 DLL3 RPS26 FERMT3 LOX RBPJ RB1 ZBTB16 LCAT CYP11B1 GIGYF2 SFTPC HSD3B7 IL12A-AS1 RECQL4 SIK3 MKKS SFTPA2 ABCA1 BNC2 IFT172 LMX1B SDHB SCARB2 RNF6 PARS2 XYLT1 CALR GP1BA GLI1 CRELD1 FGFR3 FANCF RAF1 SFTPC MPL PRKCSH ODC1 ALG10B IARS2 GPC6 GJA1 BAZ1B BRAF METTL5 JAK2 ATP6 DNAAF3 WDR19 CALM2 EBP STOX1 ICOS CALM2 DCTN1 SIX3 FKRP TMEM231 DNASE1L3 TTN SPRY2 TMEM70 FASTKD2 KIAA0586 ATF6 TRNF PLEKHM1 POU6F2 MYPN NBEAL2 SRD5A3 LRRC6 MIR17HG FGA KCNE1 B2M COG4 NHP2 CCDC22 TBC1D24 IGF2 KCNA5 CORIN TNXB MYT1L RAG2 MYL4 NDUFS8 DCAF17 PRKG1 NLRP3 FGA FOXRED1 MPLKIP TLL1 HESX1 NSMCE3 CCDC22 HADHB RPL35A EXT2 SCN1B NDUFB10 VPS35 NDUFS4 C8ORF37 ACTA1 HBB GABRD TGFBR2 APC BRCA1 AIP SNX14 SGO1 NDNF SCN5A NOTCH1 SDHD NCF2 FOXRED1 KIF5A HRAS TRNS2 ADNP PEX16 SDHD IL2RG MEFV TULP1 ATM ODAD3 RYR1 NDUFB11 CYBC1 SMPD1 CDON FIG4 DMD TREX1 ELP1 C2CD3 TWNK PNP BACH2 CRX TXNL4A CCDC115 KISS1R FUT8 ROM1 SUGCT PPA2 FAS CCNQ ERCC2 COG6 CBL PIGL GPC4 COG8 DSP NOD2 ODAD2 RAI1 CBL TGFBR2 CC2D2A MALT1 COL4A3 KDM1A SIK1 TAB2 TMEM237 SEMA4A PPARG SLC12A1 SLC37A4 VPS13A MYH7 TERT FAS TNFRSF11A COL1A2 ATOH7 DSG2 DZIP1L BCORL1 COPA AKT1 FRAS1 NSD1 LTBP4 YARS2 NPM1 DLEC1 ND6 TACR3 TMEM237 PML ND2 POLG IL12B MYMK NDE1 DISP1 ND5 TTC8 RPS10 KDM3B NODAL KIT PLG INTU CD46 HSPG2 AIPL1 RGR RSPH9 TERC CD19 CEP55 NOS3 RDH5 KCNH1 VHL GPR101 PMS2 HSD11B2 MCCC2 ANAPC1 B9D1 PGM1 TTN SLC26A3 IFT140 RNU4ATAC LMAN1 CRYAB GNS GNAO1 ABCC8 PLEC SDHB SMARCA4 RPS19 GPR101 RSPH4A AEBP1 RNASEH2C OBSL1 PEX1 LAMA4 PRPH2 FANCB ND2 POMT1 LIPA SPTB TERC CTNNB1 NR3C2 PDGFRA NTRK1 KCTD1 ANGPTL6 ASS1 ENPP1 SH3PXD2B IL2RG KRT14 RET PTGIS MED13L TRIP11 PAH PRKAR1A CNBP KCNQ1 COL2A1 CHN1 ELAC2 COG2 TMEM43 FLT4 RYR2 DBH FBXL4 ATP5F1D UNC13D SOX10 CACNA1S KCNH1 RNU4ATAC FOXH1 CDH23 PIEZO1 SOX4 JAK2 COL1A1 GTF2E2 FOXC2 NF1 PRF1 GPI GFI1B POLG AKAP10 DVL3 IGSF3 PSTPIP1 CRYAB RHO DGCR8 SMCHD1 MLH3 SIN3A SCN5A ERCC2 GATA4 SPINK5 FANCL NDUFA1 NOTCH1 NAGLU DLD STX3 MCCC1 ND2 GNPTG SDHB NEK1 POLH TMEM67 BRAF DSG2 MAN2B1 ARSA CALR HJV BRAF MYLK COL4A5 HADHB PAX3 SEMA3E RASGRP1 KIF7 LYST TKT H19 XIAP APP LRRC56 CITED2 COL4A1 FKBP14 WDPCP MCM4 RAG2 FAM149B1 PEX19 PHGDH PRKAG2 TNFRSF13C RPL26 SBDS POMT2 COL6A1 KIF7 MEFV PTEN TGFBR2 SLC2A10 OSGEP ELOVL4 SVBP VPS13B FTO RNASEH1 ALB COL1A1 GAS1 GATA4 NT5E PLN KRT14 HIC1 ANKRD11 SURF1 SIX6 RRM2B TACO1 TRNK ZFP57 VANGL1 LMNA GNPTAB FANCG TBX6 RAD51C ATN1 ELANE CASK PIGO SHH MYPN F8 KIF20A ARHGAP31 IDH2 MERTK KCNQ1 RAF1 SCNN1A PRKAR1A SIX3 CYP27A1 MUC1 DST MITF SMARCB1 RPL27 NKAP TOR1A RAI1 TRNV RBP4 RB1 DNAAF4 HPSE2 TCIRG1 FAT4 CYP3A5 CALCRL CSF2RB ALDH18A1 BMPR1A SAMD9 LPL CLDN1 NFKB2 MYD88 SELENON POLR1D STAT2 SFTPA1 TPM1 SKIV2L COL18A1 LAT TPM1 SKI KCNJ5 SEC23A LORICRIN XPC MTFMT SGCD GAS1 ATP6 STAC3 TRIP4 KCNJ2 ARX FLNA TBX1 ABCA3 GATA1 PKHD1 ZAP70 HTRA2 PAX3 VIPAS39 DYRK1A BCOR RAB23 FLCN CYP24A1 FGF23 CHRNG ACE NSD1 PIGQ TSR2 IL12A SGCB ALDH18A1 CDKN1A CCN2 ARL3 DKC1 FBN2 CASQ2 BAP1 ALX1 DSE SCN11A ROR2 HAVCR2 NDUFV2 DGUOK RIPK4 COQ2 TAB2 RPL10 PRKCD F2 CLCN2 C1S PEX7 SLC22A5 SH2B3 BUB3 GAS8 NTNG1 GNAS CYP17A1 RPGRIP1 LDLRAP1 TMEM127 ARL3 KRT1 DYNC2H1 TREX1 HOXA1 NR3C1 FGB LCAT KCNE5 PLOD3 COA3 SCNN1G TGFB3 SDHAF2 SDHD SLC39A13 STAT1 RDH12 PHOX2B TMEM237 FBN1 NRXN1 ABL1 CHD7 GP9 CTSA ERCC6 MMP2 CDAN1 CERKL PQBP1 NDUFS7 CYP11A1 LIMS2 XPA PDGFRA OFD1 VHL CDK13 FLNC LRBA TTC8 GDF2 TNNC1 PRG4 LAMC2 MMUT TRAF3IP2 KCNQ1 KATNIP FANCD2 GBA PYGL APP CR2 PIK3R2 IRF5 VPS45 PDGFRB CYP11A1 TRNQ RRM2B DSP CTSB RFC2 BCL11B NCF1 ALG1 CD3D PRCD STEAP3 MEOX1 SLC7A14 WT1 TANGO2 TLL1 TRNS1 SPTB MLYCD CASQ2 CTSA CST3 DDX59 NAGS TMEM260 ETHE1 NLRP3 PEX19 RAD21 TAPT1 MYH6 SLC7A7 INS MED12 CENPF HLA-DRB1 MAP2K1 NDUFAF4 NFIA PPA2 AFF4 POLE SMG9 MGME1 BMP2 RARA EOGT DYSF PTH1R PTH1R CACNA2D1 CBL ACTA2 GJB4 NAXD NDUFS4 NPM1 PTEN SMAD4 MTTP SOX3 TMEM216 CASK CEP290 FGA SP7 NOTCH1 PKD1L1 ACTA2 AIRE PHKG2 NDUFB8 WFS1 IFIH1 KRAS PEX1 PEX12 FBP1 CYLD VCL ZNF423 BRCC3 SLC35A1 ARSB MMP1 COLQ AGBL5 RPL27 WDR1 RHAG APOE SCNN1B AVPR2 OTULIN PIK3CA LMNA MID1 GPC3 PALLD GAS1 SOS1 AQP5 GALC MYH9 ABCC6 CRTAP RERE MKS1 PRKCSH CACNA1C KBTBD13 MKS1 ACVRL1 MPL FAT4 DOLK RIPK1 TGM5 FOXE3 DEAF1 NDUFAF8 HADHA CALM1 MRPS14 PSAP PEX12 ITGA2B PRDM6 ABCA4 LRP5 TNFRSF13B POMT2 PDE4D GRIP1 PIGW TGIF1 CLCN7 LAMP2 SMC3 MECP2 TCTN3 ATAD3A JAG1 PET100 MAPT RANGRF IL12A KRT18 TDGF1 GUCY1A1 CERKL TRNW STRADA PROS1 CDSN TGIF1 PRKAR1A ZNF687 NOTCH3 EHMT1 NOS1AP TGDS POR ANO10 TCIRG1 SDHB SPAG1 ATP6AP1 LFNG INSR CEP290 LRP1 IDUA WDR26 KRAS PHYH SDHB WNT5A SCNN1B CISD2 TRIM28 CFAP53 KRT5 POLR3A RSPH1 AKR1D1 FGFR1 TFR2 LIG4 IL7R TPM3 RMRP GNB5 DNAAF5 NXN GP1BB DNAH1 ENG KDM6A IQCB1 MINPP1 TBX20 HES7 LMOD1 TRNT GLIS3 FOXH1 TRNL1 DNAH9 DNAJC13 ALX4 ANTXR2 PRPF4 PLD1 GSN SMCHD1 RP2 ENPP1 SMARCB1 VHL TOPORS MLXIPL NKX2-5 HLA-DRB1 ADK MYH7 DNAH5 CPS1 TF CACNB2 EYA4 ND1 CPLX1 ITGB3 RYR1 CHST3 CYBB DPF2 BBS2 TP63 ERCC8 KRAS CDK10 SUFU MSX2 PEX13 GAS1 RPGRIP1L SFTPB DSP FBN1 ASCL1 GATA5 FBLN5 ISG15 GJA5 UFD1 TNFSF11 SCNN1B SERPINA6 NKX2-5 FHL1 TSC1 TXNRD2 APC PIK3CA YY1AP1 MMP2 CCDC65 GNB5 GATA6 ARID1A CACNA1S WAS SCNN1G NDUFA11 RAD21 KRT1 RAB27A MSH2 HLA-DRB1 CYP7B1 MAFB CDON PDCD10 ALX3 TBX1 TMEM67 INPP5E MYORG CCBE1 ITK LRP2 NPHP1 SCNN1A NPHP3 SCN4B PIK3C2A TMTC3 REEP6 GATA6 ELN TTC37 BTK RS1 RLIM IL7R ISCU HLA-DRB1 ACTB POMT1 LHX4 PSMB8 SAG CALM2 FANCE FCGR2A ADAMTS10 AKT3 CFHR3 RAD21 GPC4 COL11A1 UROS RAC2 CD19 NAGA CP ARL6 AIP CPT1A INVS NFIX FANCI FBN1 BAG3 DISP1 PRDM16 DNAAF5 FLRT3 NF1 FGD1 AIRE TNNC1 WNK1 PIK3CA SMARCE1 WRN BCR KCNQ1 SRCAP GP1BA TRNS2 SDHB GJA1 PCNT MRAS SGCB CASR DPM1 IDUA TOP3A ZAP70 MEN1 CYTB MYH7 NOD2 GNE ZEB2 ATP5F1E NODAL F13B LETM1 USP9X KRAS MAFB RORC PSMB9 PLAU FLT4 WNT4 TBCK ZNF469 FMR1 COX6B1 UBAC2 NKX2-5 LBR NME8 TRAC HEXA CRB2 PEX1 SLC26A2 HABP2 RERE ALMS1 AQP2 SERPING1 FOXP1 EYS RUNX1 TRNK FLT4 ASAH1 SNTA1 ACTC1 ARID1B HELLPAR KRAS DGCR2 MIF PROKR2 ABCA1 CCBE1 TSPYL1 MOG BBS5 TRPM4 STX11 IRAK1 CPLANE1 AAAS EVC PEX6 DDR2 ECE1 TMC6 FGFR2 PPP2CA RET MKKS B3GAT3 RAG2 C1R HYMAI PIBF1 TERT HMGCL ANTXR1 NDUFA11 IRX5 BTK HSD17B10 CAV3 GNAI2 RPS6KA3 CYP11B2 FTL CITED2 NDUFA12 SDHD TTN CSPP1 KCNJ2 KNSTRN TMEM216 CDON BRAF FLAD1 FZD4 ICOS TMEM126A KCNN4 FHL1 NNT PPP1CB DHDDS BMPR2 NDUFB11 ATAD3A STN1 DSC2 MYH7 NOTCH3 ERCC4 GPC4 IL36RN CNGA1 PEX16 PTPN22 NDUFA2 GATA4 GREM1 HPGD COX7B PSEN2 COL1A1 THOC2 DCLRE1C CHCHD2 GLB1 BTNL2 FLNC CCND1 TNNT2 DNAJC21 CAV1 PCCA TSC1 TRNK MEN1 DMD TNFRSF13C EPHB2 ADAMTS2 HMBS ADA2 SLC4A1 CFTR CAVIN1 C4A GANAB GBA NKX2-5 WT1 FKBP14 CLCNKB PPP1R15B SOX18 CCR6 IFNGR1 BSCL2 TCIRG1 DDX11 STAT4 PDE8B CHST3 AMER1 TMEM216 TJP2 NDUFS1 PDGFB ARVCF PROC NFKB1 MTFMT PGAP2 SLC26A2 DNM2 RECQL4 MKS1 KCNJ11 EHMT1 POLG XRCC2 KLHL7 FH RECQL4 NCF2 RPS6KA3 GGCX NDUFS8 CD28 MYH9 NT5E SLC25A20 SDHD NDUFS2 KRIT1 COL3A1 WHCR ND4L CD2AP MAP3K7 JPH2 GATA2 TRNQ LIAS RET ESCO2 SFTPB EXT1 SPEG CYP11B1 TET2 BEST1 MBTPS2 COL2A1 NF1 OFD1 ANOS1 PHGDH HRAS TKFC TALDO1 TRIM28 TCTN2 GATA4 CD79B KDM6A TRIM8 FBN1 SLC25A13 FDFT1 POLD1 MAP2K2 NFE2L2 PIK3R2 MCFD2 CAV1 DOLK COX3 SMPD1 NLRC4 ECHS1 PIK3C2A COX8A GBA DNAJC19 PIK3CD NDUFB11 ENG ATP6 ALOXE3 ND6 DPM3 PDE6D ITGB3 SRP54 SCYL1 SOX11 EBP ERCC6 F11 IL17RD SLC30A10 EPHB4 COX2 CHRM3 MVK SDHC GREB1L DNAL1 CRB1 SH2D1A PEX3 CHRNA7 GLRX5 MAP2K2 GNE ACAD9 CD27 FN1 BSCL2 LTBP2 HNRNPU NEUROD2 GATA5 SOX9 ELN KLHL7 GDF1 MAX TDP2 LTBP3 CASQ2 ADAT3 TBX20 STAG1 STAT4 ADA2 FBN1 SMAD3 FGFR2 TCOF1 GMPPB NDUFS2 FBLN5 KDM6A RYR2 MAD2L2 SPRY4 TACO1 CLN3 MPLKIP RPGRIP1L SCNN1A RPGR RFWD3 HGSNAT CCND1 PROS1 ERCC8 UPF3B CD81 CARD9 LRRC6 PORCN MED12 DNAI1 IDH3A PKP2 SCN1B CTBP1 TNFRSF1A BRCA2 TBX1 CHRNA3 MPL STX16 ERCC1 RAG1 TREX1 SMPD1 ALG8 TBXA2R CHD7 ELN HADHA A2ML1 ENG STAMBP SDHC NEK8 PDE3A CFI ELP1 SALL4 APOA5 ESPN TBL2 EMG1 WT1 SRCAP JUP DMPK PEX5 DLD PPARG DYNC2I1 CASP10 IDS LTBP2 KDM5B IRF8 GBA TRNS1 DISP1 TRNE IVD ELN SNX10 RNASEH2A LAMA4 TRIO NDUFA10 SLC25A22 ARX LDB3 GNPTAB ERCC6 CACNA1C ALOXE3 KCNH2 SRY PIGO P2RY12 FGFR3 ABCC6 LEMD3 CLEC7A WDR37 DNAAF2 NOTCH2 CAV3 FOXRED1 ZIC3 EXT1 TNFSF15 PIGA MAP3K20 FBN1 KCTD1 DMRT3 CFAP300 PIEZO2 SLC25A24 CTNNB1 SCN10A TNNT2 GPC1 RYR2 SOX2 PSEN1 DNAAF6 FOXC2 INPPL1 ITGA8 EMD NID1 SERPIND1 IFT172 GJB6 PTF1A HBA1 MYC COL11A2 PDE6A PRKCD HYLS1 TNNI3 LYST BTD KCNQ1 EZH2 MED25 SDHC CTLA4 ADD1 RYR1 MNX1 AGL NDUFAF4 RLBP1 CD244 NAGA TUBB GATA4 PTPN11 AIP SLC25A4 FKRP FHL1 EPG5 NRAS PRKAR1A HIBCH TREX1 BCOR KCNJ1 FBP1 NEB SLC35A1 DNMT3A PDGFB MRAP PTPN14 RFWD3 CDH23 RPL15 FGFR1 RNF113A NODAL BICC1 GATA1 TTC8 GBA CST3 STRA6 RAC1 WRAP53 NR0B1 PIGM TMEM70 UQCRFS1 NDUFV1 CTSH PYGM ARID2 SEC23A IRF8 VHL BLM ACTA1 CD40LG ICOS CAV3 RPS27 CFHR3 PTEN ABCC9 COX14 THPO TDGF1 GGCX MED13L KIF7 NPHP1 NDUFA13 SELENOI PIEZO1 CYTB RP1 DDX6 BRAF WDPCP HBB ZIC3 MRPL44 NOP10 WNT10A FLNA ERCC2 CALR FHL1 ACD NEB HABP2 DPP6 PHF21A MYBPC3 NIPBL ITGA2 HYOU1 EGFR ACADS DES TPM3 RPL10 MTRR PGM3 KCNQ1 MTTP IL7R STAG2 STXBP1 PSMD12 FLI1 CITED2 TMEM43 SMAD4 PRKACG IFT81 HLA-B SPINK5 KCNQ1 RNASEH2C SP110 RBM8A TIMMDC1 ATIC BAG3 SLC39A13 IGH TOP3A DPP9 TMEM231 DCLRE1C SDHD GJA5 TGFBR1 TNFRSF1B WARS2 TNNI3 GTPBP3 ITGA2B TXNL4A AP3B1 TCTN3 GPC3 DVL1 FLNB KCNQ1 TTN NDUFAF3 AGA BBS10 FOXP3 KYNU COG5 FN1 PCSK9 TRMU SOX10 DNAH1 KCNJ18 OSTM1 HADHA AKT1 FKTN BBS2 ACADVL RPL26 DISP1 RNF213 CDKN1C SH2B3 GLI2 GLI2 COL4A2 EDN1 CYP1B1 TSC1 JUP TRRAP GATAD1 CHST14 IL23R BOLA3 MGP PLIN1 CFAP300 STIM1 SCN5A UMPS CTC1 ZMIZ1 SFTPC XPC CHD4 ND6 FRG1 ANK1 FKTN STK11 SPEG AK2 MASP1 GNAQ MYCN MYH11 LRP5 SOX3 PHYH HFE CDC42 TASP1 FOXA2 DGCR6 TEK HOXD13 B3GALT6 RPL5 SLC39A4 KAT6B NEK2 ACTA1 PRKAG2 SMN1 NLRP12 GDNF CHKB ABCG8 PEX10 MVK COG1 TP63 IFT27 SPEF2 COL2A1 ABCA4 ND4 CFI LRAT ATP5MD RAD51C MLX SEC23B FUCA1 PKDCC FGB HPS4 PIGT JAK2 ALG1 AHCY FOXC1 SUZ12 PIK3CA VCL DOCK8 DNAH9 LOXL1 COX20 HCN4 KLHL41 RAI1 RMND1 PIK3CA HRAS AFF4 ERCC2 DHX38 PTPN11 KCNE2 IFT172 ND1 RIPPLY2 NDUFAF6 MYBPC3 GGCX FAM111A SPP1 NSDHL ZFPM2 NDUFAF2 TBX20 VCL SPECC1L CPT2 GYS1 CLCN7 PTCH1 LEP LBR IGLL1 NOTCH3 PPCS SCO2 PTCH1 OTUD6B PIK3CA NKX2-6 PORCN FLNA TK2 FLNC SLCO2A1 FAH XIAP HES7 GNAS MEGF8 CD3E ABCB6 KCNJ8 EPCAM ATP6V1A TDGF1 VWF PEX6 MAT2A NFIX PSMD12 SCN3B ZNF462 RNF168 TBX5 FYB1 CYB561 ATM NAA10 COL5A1 ATRX MPL SERPING1 ATP8 ACAD9 PTEN SLC12A3 SLC25A3 PKP1 CPT1A TGIF1 ADA PSMD12 UBR1 PIGN BCOR NEK9 IKZF1 AGT TSC2 LEPR WIPI2 RASA2 CARS1 EPB42 LTBP4 BTK STIM1 INF2 APOA1 RPS20 RUNX1 KCNA1 TNNT2 WT1 NDUFS2 COMT CDC73 SBDS SCNN1G ARL2BP POLH GLA CTSB CLCN7 BBS1 PIGV LAMB3 MTHFR TPM2 ANK1 STXBP2 CSRP3 ACTB PTCH1 CPOX C12ORF57 IL1RN TP53 CCDC28B SNX10 TGFB1 GP1BB ALPK3 SALL1 VPS13B NDUFAF5 STN1 HAMP XRCC4 PIGT NLRP1 ABCC9 SOX18 ELMO2 ACP5 TWIST1 FLNA TRIM37 RPL31 FLNB SRD5A3 EPB41 SLC4A1 DMD WNT4 SERPINC1 CCN2 HNRNPA2B1 RET SMAD3 RP1L1 SDHB TREX1 CNGA1 HSPG2 AARS2 ATP7A MSH6 F5 TALDO1 RPE65 C2CD3 GLI3 FGFR1 SIN3A EYS SRP54 TINF2 BUB1 ARL6 KCNE1 AHI1 SMAD4 SHPK ATP7B ERCC3 TXNRD2 SCN5A SELENON GATA6 WAS ACSL4 MAPK1 F7 KCNJ11 DOCK6 YY1AP1 PDE6C PIK3CA MEFV DLL1 FLI1 CCR1 TRDN COQ2 COX4I2 FSCN2 HIRA JAM2 KRT2 TBX1 GATC NHLRC2 ACADVL COQ4 PPARG CTLA4 GJA5 MKS1 LEMD3 HLA-DRB1 PYCR1 ADAMTS10 IGF1R CHST3 KRT10 SNRNP200 CACNB2 TBX3 PSAP RAF1 COL5A1 NABP1 FBN1 PRKAR1A NUMA1 FECH MYO18B DLL4 COL7A1 DDB2 TBX1 BMP2 FCGR2B SIX3 CALM3 SDHC LIG4 COA5 LAMA3 GMPPB MTOR NOTCH2 KAT6A BBS12 GNAQ NUP155 TP53 SCN1B SERPING1 SYT1 NPHP1 BMPR1A EGFR ABCC8 LYST LRP5 RNF125 GATA6 SCNN1A FGF8 PKD1 BBS7 BIRC3 ELN KMT2D DIS3L2 SMARCAL1 NR2F2 EPHB4 KLF1 IL6 TRNL1 KIF1B GNA11 KCNE2 ARMC5 FADD CCR6 KLHL3 HRAS HYLS1 LMX1B ADA RAG1 ACTN2 BRCA2 RPS17 SIX3 SDHA ABCB11 TNFRSF11B VWF APOE PCARE KYNU SOX4 SETD5 WDR19 TWNK POR TNFSF11 MGAT2 HK1 DNAAF6 IGHM DLX5 THOC6 TFAP2B OTX2 PEX2 SERPINF2 ZNF469 B4GALT7 CACNA1D BBS9 FGG PEX2 SETBP1 HOXA11 LMNA CTNNA3 WT1 KRT14 HYDIN CD40 CD28 SHH MNX1 SEMA4A MECP2 KCNK3 DSE ND6 DDX6 KIT FLNA B3GLCT KRAS ITCH SPAG1 TRDN GJB2 LMNB1 TSPYL1 IDUA DLL1 NDUFS4 ZNF513 FGFR3 KCNQ1 SLC19A2 PPP1CB MYOT RBBP8 TRNS1 CDON PRKACA RAG2 RPL11 KCND3 MAP2K1 MC4R STAR SCYL1 GYPC TBX4 SPATA7 NODAL GABRA3 RARB EDA2R HBB COX3 FGB MBTPS2 TMEM126B SUFU MYOCD NAA10 TSC1 PCCB FAS G6PC3 MS4A1 PROC LMNA KRT5 ZDHHC9 TRAIP RRAS2 MYH7 MED12 NEU1 CYP11B1 ZNF365 RAG1 NDUFA10 IGF2 PROP1 AUTS2 FANCD2 BCL2 TBL1XR1 PEX12 ACTC1 TWNK GATA5 LMNA DCDC2 MRE11 LMNA SEMA3A ABCA1 CNTNAP2 TMEM67 SLC2A1 BCL6 TRMT1 PSEN2 DLL1 LMX1B FOXC1 CNGB1 EMD GAS1 NDUFS3 TRAF7 HCN4 FKTN ANK1 PIGY HESX1 ACTN2 PGAP3 SMOC1 RPS29 TGIF1 PEPD TERT BAG3 ERCC8 FIG4 CDK4 TAF2 NUBPL SAMHD1 RBM20 ACTC1 MAPRE2 MAP3K7 SDHA KPTN KCNH2 ADA PIGY ATP7A IGFBP7 NUP107 C3 PKD1 CCDC141 FBLN5 NFKBIL1 PEX14 DSG2 TNFSF12 RASGRP1 GLI3 SDHA DNAL1 MLH1 MC2R AGPAT2 KCNN3 GMPPA KIT B2M FOS DYRK1A PEX7 KCNJ5 PAM16 EXOC6B ABCC9 SMO TBX1 CDKN1B CHRNG CYP7A1 ACTG2 CALM1 AMMECR1 DPM3 TMEM138 TNNI3 ADNP CYLD PAX6 KCNN3 NDUFV1 SCO2 CFAP221 RGR PKLR TSC2 MSX1 KDSR CD96 SCN2B SCN5A MFAP5 CLIP2 BEST1 PIGT PIGS SCN1B PDSS1 TGDS POR POMT2 CEP120 HNRNPA1 PPOX ATR GAS2L2 FASLG ALOX12B TPM3 IL6 AIP LDLR XRCC2 MTM1 CDKN2C PSEN1 MYH6 STAT3 IFT172 ANKRD1 SFTPA2 ITGA2B ATXN7 PDGFB B9D1 CDON ASXL1 CDKN2B COL3A1 TTPA PDHA1 MAGEL2 INSR PARN MAP1B NRAS NPC2 TP63 PRKG1 MYH7 PKD2 BLNK DIS3L2 DES CSF2RA SMOC1 MYPN ZIC2 SH2B3 HACD1 TBC1D24 AHCY CEP290 PCNA SUFU GPX4 PRPF3 NONO IFT80 EXT2 MYMK PARN FGFR3 SCN5A XPNPEP3 COQ9 TP53 NAGA NAGA TAZ CACNA1H SLC22A4 KCNAB2 USF3 GCK H19 HDAC4 ND5 PTCH1 SCN5A CR2 MYPN TNPO3 F5 F5 MPL HADH SERPINF2 DSP SHH HSD3B7 NDUFB11 AK2 ND4 ASXL1 GLI2 MYOC AHR TNFRSF11A SRSF2 SDHB NUP107 GATA6 TET2 SCN2B CCDC8 CTC1 KITLG NDUFV2 TBX1 IMPDH1 IGBP1 ENPP1 CFAP410 SOX6 PACS2 GPX4 BMPR1A SKI ASXL2 TERC ADAMTS3 TOPORS COG7 PUF60 CAP2 AGPAT2 MRPL12 TTN DVL3 IFT43 DSG1 SOX10 SNIP1 SCNN1G TBX2 GNB3 NGLY1 TF CYBA PIEZO1 SEC63 TMEM126B INTS1 CDIN1 FRG1 GBE1 TRNW RTEL1 PEX5 TET3 PCNA KRT8 MYPN ITCH PNPLA2 FOXP1 GNB5 MYO5B DNAAF1 PEX7 FGFRL1 AMMECR1 SUMF1 MTMR14 TPM1 FGFR2 CREBBP PDE6G NDUFAF2 CEP19 APC NDP HLA-DRB1 TERT PTPRC MC1R SCN10A GDAP1 SMO NAA10 ERCC6 SFTPB CACNA1S EPHB4 KAT6B NDUFB9 RFT1 CFAP298 ACTA2 KIF1B CPT2 IQSEC2 NSMCE2 COA8 DNAJC19 MYLK2 MESP2 ERF WDPCP ZEB2 SIM1 TANC2 LIPC TAZ FBXW11 TPK1

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook